



City Research Online

City St George's, University of London

Citation: Rabiolo, A., Montesano, G., Crabb, D. P., Garway-Heath, D. F., Bunce, C., Lascaratos, G., Amalfitano, F., Anand, N., Azuara-Blanco, A., Bourne, R. R., et al (2024). Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study. *Ophthalmology*, 131(8), pp. 302-913. doi: 10.1016/j.ophtha.2024.02.008

This is the accepted version of the paper.

This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/33074/>

Link to published version: <https://doi.org/10.1016/j.ophtha.2024.02.008>

Copyright and Reuse: Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).

Ophthalmology

Relationship between intraocular pressure fluctuation and visual field progression rates in the United Kingdom Glaucoma Treatment Study --Manuscript Draft--

Manuscript Number:	OPHTHA-D-23-01872R3
Article Type:	Manuscript
Keywords:	visual field progression; ocular pulse amplitude; Risk factors; linear mixed models.
Corresponding Author:	David Garway-Heath, MD Moorfields Eye Hospital NHS Foundation Trust UNITED KINGDOM
First Author:	Alessandro Rabiolo, MD FEBO
Order of Authors:	Alessandro Rabiolo, MD FEBO Giovanni Montesano, MD David P Crabb, PhD David F Garway-Heath, MD, FRCOphth
Abstract:	Purpose. To investigate whether intraocular pressure (IOP) fluctuation is independently associated with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Design. Randomized, double-masked, placebo-controlled multicenter trial. Participants: Participants with ≥ 5 VFs (213 placebo, 217 treatment). Methods. Associations between IOP metrics and the VF progression rates (mean deviation (MD) and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean ocular pulse amplitude (OPA), standard deviation (SD) of diurnal IOP (diurnal fluctuation), and SD of IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from mean IOP. Correlated non-fluctuation IOP metrics (baseline, peak, mean, supine and peak phasing IOP) were combined with principal component analysis (PCA), and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modelled the effect of the variables on VF rates. IOP was measured with Goldmann applanation tonometry and OPA with Pascal tonometry. Analyses were conducted separately in the two treatment arms. Main Outcome Measures. Associations between IOP fluctuation metrics and rates of MD and five fastest test locations. Results. In the placebo arm, only PC1 was significantly associated with the MD rate (estimate [standard error (SE)]: -0.19 [0.04] dB/year, $p < 0.001$), while normalized IOP fluctuation metrics were not. No variable was significantly associated with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate [SE]: -0.58 [0.16] dB/year, $p < 0.001$), CCT (estimate [standard error (SE)]: 0.26 [0.10] dB/year for 10 μm thicker, $p = 0.01$) and normalized OPA (estimate [SE]: -3.50 [1.04] dB/year, $p = 0.001$) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate [SE]: -0.27 [0.12] dB/year, $p = 0.028$) was associated with the rates of progression. Conclusions. There is no evidence to support that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. OPA may be an independent factor for faster glaucoma progression.
Suggested Reviewers:	
Opposed Reviewers:	
Response to Reviewers:	AE Comment: Dear authors, Congratulations on your work. I have one suggestion. In the Precis (and everywhere else where the same issue is present), please insert "either" in front of "diurnal" and replace "and" with "or" in front of "long-term". The way it now stands, one could conclude that diurnal fluctuation and long-term fluctuation are risk factors, but are not independent of one another. Does that make sense? Best

wishes, Henry Jampel

Authors' Response: We thank the Associate Editor for his positive feedback. We have now modified the precis, abstract, and discussion accordingly.

Change in the Manuscript:

Precis

"This exploratory analysis of the multicenter randomized placebo-controlled United Kingdom Glaucoma Treatment Study found no evidence to support that either diurnal or long-term IOP fluctuation are independent factors for glaucoma progression."

Abstract, page 4, lines 30-33

"Conclusions. There is no evidence to support that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative."

Discussion, page 29, lines 595-597

"In conclusion, this study finds no evidence to support that either diurnal or long-term IOP fluctuation, defined in a clinically relevant manner, are independent factors for glaucoma progression."

February 3rd, 2024

Russell N. Van Gelder, MD PhD
Chief Editor
Ophthalmology

Dear Editor,

Thank you for considering our manuscript OPHTHA-D-23-01872, "**Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS)**" for publication in the *Ophthalmology* journal. The points raised by the Associate Editor and Editorial office have all been considered and changes incorporated into the revised manuscript where appropriate. Attached is a point-by-point response to each of these comments. Any changes to the manuscript are italicized and in quotes in the response letter.

All the authors have approved the revised manuscript for submission to the *Ophthalmology* journal. As Corresponding Author, I had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis, as well as the decision to submit it for publication.

Thank you for your consideration of our manuscripts and we look forward to your response.

Yours sincerely,

David F Garway-Heath
Moorfields Eye Hospital
162 City Rd, London EC1V 2PD
United Kingdom
e-mail: d.garwayheath@nhs.net

POINT-BY-POINT RESPONSE FORM

Please list the editor's, reviewer(s)', and editorial office's comments in the left-hand column, spacing them so that you can insert the relevant response in the center column and the respective point(s) in the text (and tables or legends, if appropriate) in the right-hand column. Adding line numbers to the manuscript file and referring to specific line numbers will be useful in determining which parts of the manuscript changed.

Manuscript #: OPHTHA-D-23-01872

Manuscript title: Relationship between intraocular pressure fluctuation and visual field progression rates in the United Kingdom Glaucoma Treatment Study

Suggestion, Question, or Comment from the Editor	Author's Response	Change in the Manuscript
Dear authors, Congratulations on your work. I have one suggestion. In the <i>Precis</i> (and everywhere else where the same issue is present), please insert "either" in front of "diurnal" and replace "and" with "or" in front of "long-term". The way it now stands, one could conclude that diurnal fluctuation and long-term fluctuation are risk factors, but are not independent of one another. Does that make sense? Best wishes, Henry Jampel	We thank the Associate Editor for his positive feedback. We have now modified the <i>precis</i>, abstract, and discussion accordingly.	<u>Precis</u> <i>"This exploratory analysis of the multicenter randomized placebo-controlled United Kingdom Glaucoma Treatment Study found no evidence to support that either diurnal or long-term IOP fluctuation are independent factors for glaucoma progression."</i> <u>Abstract, page 4, lines 30-33</u> <i>"Conclusions. There is no evidence to support that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative."</i> <u>Discussion, page 29, lines 595-597</u> <i>"In conclusion, this study finds no evidence to support that either diurnal or long-term IOP fluctuation, defined in a clinically relevant manner, are independent factors for glaucoma progression."</i>

Suggestion, Question, or Comment from the Editorial Office	Author's Response	Change in the Manuscript
If your paper includes a study group/writing committee authorship, please upload the complete study group/writing committee list as a Word document "Collaborators" file to the submission.	We have now included a Word document "Collaborators" file listing the UKGTS investigators.	N/A

PRECIS

This exploratory analysis of the multicenter randomized placebo-controlled United Kingdom Glaucoma Treatment Study found no evidence to support that either diurnal ~~and-or~~ long-term IOP fluctuation are independent factors for glaucoma progression.

- Manuscript -

Relationship between intraocular pressure fluctuation and visual field progression rates in the United Kingdom Glaucoma Treatment Study

Authors: Alessandro Rabiolo, MD, FEBO¹⁻³; Giovanni Montesano, MD^{1,4}; David P Crabb PhD⁴; David F Garway-Heath, MD, FRCOphth¹, on behalf of the United Kingdom Glaucoma Treatment Study Investigators

~~United Kingdom Glaucoma Treatment Study investigators:~~

~~David F. Garway-Heath MD, David P. Crabb PhD, Catey Bunce DSc, Gerassimos Lascaratos MSc, Francesca Amalfitano BSc, Nitin Anand MD, Augusto Azuara-Blanco PhD, Rupert R. Bourne MD, David C. Broadway MD, Ian A. Cunliffe FRCOphth, Jeremy P. Diamond PhD, Scott G. Fraser MD, Tuan A. Ho MSc, Prof Keith R. Martin DM, Andrew I. McNaught MD, Anil Negi MD, Krishna Patel MSc, Richard A. Russell PhD, Ameet Shah MRCOphth, Paul G. Spry PhD, Katsuyoshi Suzuki PhD, Edward T. White BSc, Richard P. Wormald FRCOphth, Wen Xing MSc, Thierry G. Zeyen PhD~~

Authors affiliation:

- (1)** NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom.
- (2)** Ophthalmology Unit, University Hospital Maggiore della Carità, Novara, Italy.
- (3)** Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", Novara, Italy.

(4) Optometry and Visual Sciences, City University of London, London, London, United Kingdom.

Corresponding author: Prof David F Garway-Heath, Moorfields Eye Hospital, London EC1V 2PD, UK; d.garwayheath@nhs.net

Short title: IOP fluctuation and glaucoma progression rates in the UKGTS

Conflict of Interest: None of the authors has any competing interest.

Financial Disclosures: Alessandro Rabiolo has received support for attending meetings from Thea Farma spa, Bausch + Lomb, and Visufarma spa. Giovanni Montesano has received consulting fees from Alcon Inc, CenterVue-Icare, and Omikron spa, has received speaker fees and support for attending meetings from Omikron spa, and has leadership role in the Relayer Ltd. David Crabb: Consultant/Contractor for Allergan, Apellis Pharmaceuticals, CenterVue-Icare, Thea, Roche; non-remunerative relationship with Santen, Medisoft; Financial Support from Santen, AbbVie, Apellis Pharmaceuticals, CenterVue-Icare. David Garway-Heath has the following disclosure: Consultant/Contractor for AbbVie, Genentech, Janssen, Novartis, Omikron, Roche, Santen; Financial Support from Alcon Research Institute, Janssen, Santen.

Financial support: The trial sponsor was Moorfields Eye Hospital NHS Foundation Trust. The principal funding was through an unrestricted investigator-initiated research grant from Pfizer, with supplementary funding from the UK's NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. Equipment loans were made by Heidelberg Engineering, Carl Zeiss Meditec and Optovue (Optovue, Fremont, CA,

USA). DFG-H's chair at UCL is supported by funding from the nonprofit association Glaucoma UK.

Presented at: Association for Research in Vision and Ophthalmology

Annual Meeting, May 2022, Denver, Canada; 15th European Glaucoma Society

Congress, June 2022, Athens, Greece.

ABSTRACT

Purpose. To investigate whether intraocular pressure (IOP) fluctuation is independently associated with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study.

Design. Randomized, double-masked, placebo-controlled multicenter trial.

Participants: Participants with ≥ 5 VFs (213 placebo, 217 treatment).

Methods. Associations between IOP metrics and the VF progression rates (mean deviation (MD) and five fastest locations) were assessed with linear mixed models.

Fluctuation variables were mean ocular pulse amplitude (OPA), standard deviation (SD) of diurnal IOP (diurnal fluctuation), and SD of IOP at all visits (long-term

fluctuation). Fluctuation values were normalized for mean IOP to make them

independent from mean IOP. Correlated non-fluctuation IOP metrics (baseline, peak,

mean, supine and peak phasing IOP) were combined with principal component

analysis (PCA), and principal component 1 (PC1) was included as a covariate.

Interactions between covariates and time from baseline modelled the effect of the

variables on VF rates. IOP was measured with Goldmann applanation tonometry and

OPA with Pascal tonometry. Analyses were conducted separately in the two

treatment arms.

Main Outcome Measures. Associations between IOP fluctuation metrics and rates of MD and five fastest test locations.

Results. In the placebo arm, only PC1 was significantly associated with the MD rate (estimate [standard error (SE)]: -0.19 [0.04] dB/year, $p < 0.001$), while normalized IOP

fluctuation metrics were not. No variable was significantly associated with MD rates

in the treatment arm. For the fastest five locations in the placebo group, PC1

(estimate [SE]: -0.58 [0.16] dB/year, $p < 0.001$), CCT (estimate [standard error (SE)]:

0.26 [0.10] dB/year for 10 μ m thicker, $p=0.01$) and normalized OPA (estimate [SE]: -3.50 [1.04] dB/year, $p=0.001$) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate [SE]: -0.27 [0.12] dB/year, $p=0.028$) was associated with the rates of progression.

Conclusions. There is no evidence to support that either diurnal ~~and-or~~ long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. OPA may be an independent factor for faster glaucoma progression.

Keywords: visual field progression; ocular pulse amplitude; risk factors; linear mixed models.

INTRODUCTION

Intraocular pressure (IOP) is an established risk factor for glaucoma progression, and lowering IOP is currently the only available treatment to slow the disease progression.¹⁻⁴ Longitudinal measurement of IOP is crucial in evaluating glaucoma patients, estimating their risk of developing progressive glaucomatous damage, and assessing their response to treatment.

IOP is subject to fluctuations over time. Several IOP-derived parameters are commonly used in clinical practice and research to summarize the behavior of IOP, including mean IOP (average of IOP over multiple visits), peak IOP (highest IOP reading over follow-up), and IOP fluctuation (standard deviation [SD] or range IOP over time). Many studies have shown that mean IOP and peak IOP are independently associated with glaucoma progression;^{1, 2, 5, 6} on the other hand, the exact role of IOP fluctuation is still debated, with discordant results reported in the literature.⁵⁻¹⁰ Elucidating the role of IOP fluctuation is difficult for several reasons. IOP fluctuation is tightly correlated with other IOP-related metrics (e.g., mean IOP), making it difficult to isolate its role as an independent factor. IOP fluctuation may be artificially increased by escalating treatment in patients with suspect progression. The effect of IOP fluctuation may not be uniform, varying as a function of the disease stage, treatment status, mean IOP values, and definition of fluctuation.¹¹

This planned secondary analysis of the United Kingdom Glaucoma Treatment Study (UKGTS) randomized controlled trial aimed to evaluate whether IOP fluctuation, as assessed by ocular pulse amplitude (OPA), diurnal variation and between-visit variation, is independently associated with the rate of visual field progression. The UKGTS is ideal for this purpose because there were no treatment

- 62 escalations artificially increasing IOP fluctuation, and the dataset allows evaluation of
- 63 IOP metrics in both untreated and treated glaucoma patients.

METHODS

Study Population and Procedures

This study was a planned secondary analysis of data from the UKGTS, which was a multicenter, randomized, triple-masked, placebo-controlled trial investigating the ability of Latanoprost, an IOP lowering medication, to preserve visual function in newly diagnosed open-angle glaucoma patients (trial registration number, ISRCTN96423140). The UKGTS and the subsequent analysis of anonymized data in this study complied with the tenets of the Declaration of Helsinki and were approved by local institutional review boards (Moorfields and Whittington Research Ethics Committee on June 1, 2006, ethics approval reference, 09/H0721/56). All patients provided written informed consent at the time of enrolment in the trial.

The UKGTS study protocol, baseline characteristics, and outcomes have been published elsewhere.^{3, 12, 13} Participants recruited in 10 ophthalmology institutions across the United Kingdom were randomized 1:1 to receive latanoprost 0.005% or placebo eye drops once in the evening in both eyes for 24 months or until meeting an endpoint. The UKGTS included patients ≥ 18 years of age and newly diagnosed treatment-naïve open-angle glaucoma, including primary open-angle and pseudoexfoliation glaucoma. Exclusion criteria were: advanced glaucoma, as defined by visual field mean deviation < -10 dB in the better eye or < -16 dB in the worse eye, mean baseline IOP ≥ 30 mmHg, Snellen best-corrected visual acuity (BCVA) $< 6/12$, and poor image quality (>40 μm mean pixel height standard deviation) with the Heidelberg retina tomograph (Heidelberg Engineering, Heidelberg, Germany).

Potentially eligible participants underwent two pre-randomization visits. After meeting the study criteria and signing the written informed consent, participants were

randomized either to receive latanoprost 0.005% or placebo eye drops. Enrolled subjects underwent IOP measurement, VF, and imaging at eleven post-randomization visits over 24 months or until meeting an endpoint. Standard automated perimetry with the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) was performed with stimulus size III, Swedish Interactive Threshold Algorithm (SITA) standard strategy, and 24-2 grid. VF testing was performed at all 11 scheduled visits over 24 months, and tests were clustered (2 VFs on the same day) at baseline, 2 months, 16 months, 18 months, and 24 months. In this exploratory analysis, we included participants from the UKGTS with ≥ 5 reliable visual fields (VFs). Reliable VFs were defined as those with false positives less than 15%, while no limits for false negatives and fixation losses were applied. At the first post-randomization visit, the following demographic variables were collected: age, sex, ethnicity, family history of glaucoma, history of systemic diseases (i.e., systemic hypertension, cardiovascular disease, diabetes, heart attack, stroke, sleep apnea, migraine, Raynaud's phenomenon, vasospasm, angina, claudication), and smoking status. The following investigations were also performed: blood pressure measurements with the Omron M7 Blood Pressure Monitor (Matsusaka, Mie, Japan), weight, height, slit-lamp examination, refractive error measured either with an autorefractor or from spectacle focimetry (if not available, the spherical equivalent of the trial lens was used in the visual field test, based on participants' age), axial length measurement with the IOL Master (Carl Zeiss Meditec, Dublin, CA), and central corneal thickness (CCT) measured with an ultrasound pachymeter. We included one eye per patient; specifically, the eye with the worst baseline VF mean deviation (MD).

114 *IOP Metrics*

115 At all visits, IOP was measured with Goldmann applanation tonometry (GAT;
 116 Haag Streit, Koeniz, Switzerland), Pascal dynamic contour tonometry (Ziemer
 117 Ophthalmic Systems AG, Zurich, Switzerland), and the Ocular Response Analyzer
 118 (Reichert, Inc., Buffalo, NY). Diurnal GAT phasing with IOP measured every 2 hours
 119 from 9 am to 5 pm was performed at the first post-randomization and at the final visit.
 120 At the first post-randomization visit, supine IOP was measured with Perkins
 121 applanation tonometer.

122 The following IOP metrics were calculated and used for the analyses:

- 123 • Baseline pretreatment IOP, defined as the average of the IOP readings obtained
 124 in the two pre-randomization visits.
- 125 • Mean IOP, defined as the average of all post-randomization IOP readings.
- 126 • Peak IOP, defined as the highest IOP reading of all post-randomization IOP
 127 readings.
- 128 • Supine IOP, defined as the Perkins applanation tonometry IOP readings
 129 measured at the first post-randomization visit.
- 130 • Phasing peak IOP, defined as the highest IOP reading of the diurnal phasing
 131 performed at the first post-randomization visit.
- 132 • Diurnal IOP fluctuation, defined as the SD of IOP measurements obtained from
 133 the diurnal IOP phasing performed at the first post-randomization visit. Diurnal
 134 IOP fluctuation was also calculated using the IOP measurements from the last
 135 post-randomization visit.
- 136 • Long-term IOP fluctuation, defined as the SD of post-randomization IOP
 137 readings.

- Mean ocular pulse amplitude (OPA) from the Pascal Dynamic Contour tonometry. OPA was defined as the range of the pulse wave contour and provides a measure of how IOP fluctuates over cardiac cycle. We used the average of all post-randomization OPA values.

Statistical Analysis

We performed all statistical analyses with the open-source software R (R Foundation for Statistical Computing, Vienna, Austria). Variable distributions were inspected with histograms and quantile-quantile plots. We reported mean ($\pm$ Standard deviation [SD]) and median (interquartile range [IQR]) for Gaussian and non-Gaussian variables, respectively. We reported frequencies and proportions for discrete variables. Proportion and pattern of missing data were analyzed. All analyses were conducted with complete cases. All tests were 2-tailed, and p-values <0.05 were considered statistically significant.

Demographic and clinical characteristics between the two treatment groups were compared with t-test and chi-squared test for continuous and categorical variables, respectively. Agreement between diurnal IOP fluctuation calculated on the first and last post-randomization visit was investigated with Bland-Altman statistics. We also collected the timing of each IOP measurement and calculated the absolute differences from each measurement and the mean time of day for each patient's IOP measurements.

Linear models were used to evaluate the relationship between (i) mean IOP and long-term IOP fluctuation, (ii) mean IOP and long-term IOP fluctuation/mean IOP, (iii) mean diurnal IOP and diurnal IOP fluctuation, (iv) mean diurnal IOP and diurnal IOP

fluctuation/mean diurnal IOP, (v) mean OPA and mean IOP, and (vi) mean OPA/GAT IOP and mean IOP.

IOP fluctuation is known to be positively correlated with mean IOP. Additionally, measurement error can contribute to the variability in IOP measurements, potentially confounding true IOP fluctuation. To obtain a measure of IOP fluctuation which is independent from mean IOP, we performed a normalization of IOP fluctuation values. Specifically, we ran a linear regression of IOP fluctuation against mean IOP. We then divided the observed IOP fluctuation values by the corresponding predicted values. This process was applied distinctly for each fluctuation metric. For long-term fluctuation, we utilized the SD of all post-randomization IOP readings and their corresponding mean IOP values from all post-randomization readings. For diurnal fluctuation, we used the SD and mean IOP measurements from the diurnal IOP phasing conducted during the first post-randomization visit. For the OPA, we used the average of all post-randomization ORA values for each subject and their corresponding mean IOP across all available post-randomization visits. For OPA, we calculated the average of all post-randomization ORA values for each subject, alongside their corresponding mean IOP from all available post-randomization visits.

As shown in Figure S1, normalized IOP fluctuation was unrelated to mean IOP. Normalization was further performed on the two study arms separately, leading to almost identical results (data not shown). All analyses were conducted on both normalized and unnormalized IOP fluctuations values.

Linear mixed models with random slopes and random intercepts were used to estimate the rates of progression and investigate associations between the rate of visual field progression and variables of interest. Linear mixed models are an extension of traditional linear models, which can accommodate the repeated-

187 measure (e.g., multiple measurements from the same eye over time) and clustered
188 (multiple test locations from the same VF) nature of data. We first look at univariable
189 associations between the MD rate of change and each variable of interest. In all
190 models, the MD value at each visit was the outcome variable; the follow-up time in
191 years, the covariate of interest, and their interaction were the fixed effects; the eye
192 identification number and follow-up time were the random intercept and random
193 slope terms, respectively, to account for the repeated measure of data and for the
194 fact that different eyes may have different rates of progression over time. Interactions
195 between covariates and time from baseline modeled the variables' effect on the
196 progression rate. We then built multiple variable linear mixed models to account for
197 the impact of fluctuation metrics after adjusting for all other potentially confounding
198 factors, including other IOP metrics. Correlations among candidate covariates were
199 tested with a hierarchical cluster analysis based on the absolute value of Spearman
200 correlations (Figure S2). Some of the variables measuring the magnitude of IOP
201 elevation exhibited high correlations. Highly correlated variables are a source of
202 multicollinearity, causing unstable regression coefficients and large standard errors.
203 To address this issue, all correlated metrics measuring IOP (baseline IOP, peak IOP,
204 mean IOP, supine IOP, peak phasing IOP) were combined using Principal
205 Component Analysis (PCA). These variables had a |Spearman rho| of 0.50 or
206 greater. PCA extracts uncorrelated orthogonal vectors (Principal Components [PCs])
207 from multiple correlated variables. PCs are ranked, with the first PC (PC1) being the
208 one containing the largest amount of combined information from the correlated
209 variables. PCA was performed on standardized data, with zero mean and unit
210 variance. We inspected the PCA model with biplots and scree plots (Figure S3).
211 Scree plots were used to visualize the amount of variance explained by the various

Principal Components and to select the number of PCs to retain for subsequent analyses. PC1 was selected for further analyses, as it explained 81% of the overall variance in the PCA, and used as a fixed effect in the multivariable linear mixed models. The Interaction between PC1 and follow-up time modelled the effect of PC1 on visual field progression rates, as previously explained. PCA was also performed on the two study arms separately, leading to similar results (data not shown).

Similar analyses were run in a pointwise manner, including: (i) all 52 VF test locations of the 24-2 grid (after excluding the two locations corresponding to the blind spot), and (ii) the five fastest progressing locations for each study eye (which is conceptually similar to the event-based GPA analysis which identifies the 3 or more locations most different from baseline). Models conducted on the pointwise threshold sensitivity data had a nested random intercept with eye identification number over the test location number to account for the inclusion of multiple pointwise series from the same eye. All models were run separately in the placebo and treatment arms. Regression estimates along with their 95% confidence intervals (95% CIs) and p-values were reported.

RESULTS

Of the 461 participants with longitudinal data included in the primary UKGTS analysis, 31 were excluded because of an insufficient number of VFs. The remaining 430 (placebo arm: 213, treatment arm: 217) participants were included in this study. As shown in Figure S4, most variables had complete observations, with only a few variables having missing observations. Spherical equivalent, CCT, and supine IOP values were missing in 26 eyes (6%), 16 (3.7%), and 15 eyes (3.5%), respectively. Mean arterial pressure, body mass index, ethnicity, corneal hysteresis, peak and mean phasing IOP, and diurnal fluctuation were missing in less than 2% of patients. All other variables had no missing data.

Baseline characteristics of the UKGTS study population have been published elsewhere.^{3, 12} Table 1 illustrates the main demographic and clinical characteristics of the patient cohort. Patients in the treatment cohort had significantly longer follow-up time than those in the placebo cohort, with a median (IQR) of 1.9 (1.3 to 2.0) and 1.6 (1.0 to 2.0) years, respectively ($p=0.004$). The number of VFs was also significantly greater ($p=0.027$) in the treatment arm (median [IQR]: 15 [10-16]) than in the placebo arm (median [IQR]: 13 [10-16]). In the post-randomization study period, patients in the treatment arm showed higher mean corneal hysteresis than those in the placebo arm (mean [$\pm$ SD]: 9.4 [$\pm$ 1.6] vs. 8.9 [$\pm$ 1.6] mmHg, $p=0.003$). As shown in Figure 5, all post-randomization IOP metrics were significantly different between the two arms ($p<0.045$ or below), except for normalized diurnal IOP fluctuation ($p=0.89$) and normalized OPA ($p=0.93$). The median of the absolute differences from the mean time of day for each patient's IOP measurements was 1.1 hours, with an interquartile range (IQR) of 0.5 hours (30 minutes) to 2.0 hours.

253 *Global MD rate*

254 The distribution of MD rates in the two groups as estimated with linear mixed
255 models is illustrated in Figure 6. Median (IQR) MD rates in the placebo and
256 treatment cohort were -0.23 (-0.73 to 0.11) dB/year and 0.13 (-0.30 to 0.37) dB/year,
257 respectively ($p<0.001$).

258 In the univariable analysis (Table S2), higher values of all non-fluctuation IOP
259 parameters, including pretreatment baseline IOP (estimate [standard error (SE)]: -
260 0.06 [0.02] dB/year for 1 mmHg increase, $p<0.001$), mean IOP (estimate [SE]: -0.08
261 [0.02] dB/year for 1 mmHg increase, $p<0.001$), peak IOP (estimate [SE]: -0.07 [0.01]
262 dB/year for 1 mmHg increase, $p<0.001$), peak phasing IOP (estimate [SE]: -0.05
263 [0.02] dB/year for 1 mmHg increase, $p<0.001$), and supine IOP (estimate [SE]: -0.06
264 [0.01] dB/year for 1 mmHg increase, $p<0.001$), were significantly associated with
265 faster MD rates in the placebo group. With regards to the IOP fluctuations
266 parameters, higher long-term IOP fluctuation (estimate [SE]: -0.27 [0.07] dB/year for
267 1 mmHg increase, $p<0.001$) and OPA (estimate [SE]: -0.32 [0.09] dB/year for 1
268 mmHg increase, $p<0.001$) were associated with faster MD rates of change, while
269 diurnal IOP fluctuation was not ($p=0.23$). None of the fluctuation parameters was
270 associated with the MD rate after normalizing for the mean IOP ($p=0.11$ or above). In
271 the treatment arm, none of the variables was significantly associated with the MD
272 rate, except for long-term IOP fluctuation (estimate [SE]: -0.12 [0.06] dB/year for 1
273 mmHg increase, $p=0.047$).

274 Results of the multivariable model for factors associated with MD rate of
275 progression are illustrated in Figure 7 and detailed in Table S3. In the placebo arm,
276 PC1, which combined information from all the non-fluctuation IOP parameters, was
277 the only factor associated with the MD rate (estimate [SE]: -0.19 [0.08] dB/year for 1

unit increase, $p < 0.001$), while the various normalized IOP fluctuation metrics were not. Thinner CCT had an association of borderline statistical significance with faster VF progression rates (estimate [SE]: 0.05 [0.02] dB/year for 10 μm thicker, $p = 0.06$). None of the variables was significantly associated with the MD rate of progression in the treatment arm. Older age was associated with faster MD rates (estimate [SE]: -0.12 [0.06] dB/year for a 10-year increase) in the treatment arm, but this only approached nominal statistical significance ($p = 0.06$). Similar results were obtained when analyzing unnormalized IOP fluctuation metrics (Table S4).

Pointwise Rates

Figure 6 illustrates the distribution of pointwise progression rates in the two groups. Pointwise rates were significantly faster in the placebo group than in the treatment group (median [IQR]: -0.42 [-0.59 to -0.26] dB/year vs. 0.03 [-0.14 to 0.19] dB/year, $p < 0.001$). Results of the univariable analysis for factors associated with the pointwise rates of change are illustrated in Table S5. In the placebo group, all the non-fluctuation IOP parameters were significantly associated with the pointwise rates ($p = 0.003$ or below). Higher unnormalized long-term IOP fluctuation (estimate [SE]: -0.34 [0.13] dB/year for 1 mmHg increase, $p = 0.008$) and OPA (estimate [SE]: -0.65 [0.15] dB/year for 1 mmHg increase, $p < 0.001$) were associated with faster pointwise rates of progression. After normalizing IOP fluctuations for mean IOP, only OPA was associated with the rate of progression (estimate [SE]: -1.36 [0.48] dB/year for 1 unit increase, $p = 0.005$). In the treatment arm, none of the IOP variables was associated with the pointwise rates of progression. In the multiple variable model (Figure 8 and Table S6), normalized mean OPA was associated with the pointwise rates of progression in the placebo arm (estimate [SE]: -1.23 [0.46] dB/year for 1 unit

increase, $p=0.009$), but not in the treatment arm. None of the other fluctuation metrics was associated with the rate of progression in either group. The combined IOP metric, PC1, was associated with the pointwise rate of change in the placebo group ($p<0.001$), but not in the treatment group ($p=0.42$). Similarly, none of the unnormalized IOP fluctuation metrics was associated with the pointwise rate of change metrics (Table S7), except for mean OPA in the placebo group (estimate [SE]: -0.47 [0.17] dB/year for 1 mmHg increase, $p=0.008$).

For the five fastest progressing locations, median (IQR) pointwise rates of the five in the placebo and treatment cohort were -1.00 (-1.49 to -0.80) dB/year and -0.52 (-0.93 to -0.34) dB/year, respectively ($p<0.001$). Results of the univariable analysis for factors associated with the rates of the fastest five locations are illustrated in Table S8. In the placebo group, all the non-fluctuation IOP parameters were significantly associated with the pointwise rates ($p=0.003$ or below). Higher unnormalized (estimate [SE]: -1.67 [0.34] dB/year for 1 mmHg increase, $p<0.001$) and normalized OPA (estimate [SE]: -3.95 [1.10] dB/year for 1 unit increase, $p<0.001$) were associated with faster rates of progression. In the treatment arm, higher unnormalized long-term IOP fluctuation was associated with faster rates of progression (estimate [SE]: -0.46 [0.17] dB/year for 1 mmHg increase, $p=0.006$), but the association was no longer significant after normalizing IOP fluctuation (estimate [SE]: -0.81 [0.44] dB/year for 1 unit increase, $p=0.06$). In the multiple variable model (Figure 9 and Table S9), CCT (estimate [SE]: 0.26 [0.10] dB/year for 10 μm thicker, $p=0.01$), normalized OPA (estimate [SE]: -3.50 [1.04] dB/year for 1 unit increase, $p=0.001$), and PC1 (estimate [SE]: -0.58 [0.16] dB/year for 1 PC1 unit increase, $p<0.001$) were associated with the rates of progression of the fastest five test locations in the placebo group; while normalized diurnal and long-term IOP

328 fluctuations were not. In the treatment group, PC1 (estimate [SE]: -0.27 [0.12]
329 dB/year for 1 PC1 unit increase, $p=0.028$) was the only factor associated with
330 progression rates. Results of the nonnormalized models are shown in Table S10.
331 All analyses were repeated with mean IOP, peak IOP and normalized LTF fluctuation
332 calculated from corneal compensated IOP as measured with the Ocular Response
333 Analyzer (Reichert, Inc, Buffalo, NY) and lead to similar results (Figures S10-S14).

DISCUSSION

In this study, we evaluated whether IOP fluctuation was associated with the rate of glaucomatous visual field progression. We provided a comprehensive evaluation of clinically relevant definitions of IOP fluctuation over the course of seconds (OPA), office hours (diurnal fluctuation), and multiple visits over the entire follow-up (long-term fluctuation). We found that higher OPA was associated with faster rates of progression, while diurnal or long-term IOP fluctuations were not associated with the rate of progression. Elevated IOP metrics (e.g., mean IOP, peak IOP) were consistently associated with the rate of VF progression.

Establishing the relationship between IOP fluctuation and the rates of visual field progression is not an easy task for many reasons. First, IOP fluctuation may vary as a function of the time frame over which it is calculated, and there is no consensus on which type of fluctuation is most informative. Our study provided a comprehensive approach, analyzing three measures of fluctuations. Second, the definition of IOP fluctuation is not uniform across studies, with IOP range and SD IOP usually used as measures for IOP fluctuation. It has been suggested that SD IOP could be a more robust metric than range IOP as the latter may be heavily influenced by outliers and does not account for the number of IOP measurements.⁸ In this study, we used SD IOP to calculate diurnal and long-term IOP fluctuation; on the other hand, OPA, a measure of very short-term fluctuation, was an average range of several cardiac cycles. We further mitigated the effect of potential outliers on OPA by obtaining two consecutive OPA measurements at each time point, averaging them to have a single value, and then averaging the resulting values throughout all available follow-up visits. Third, isolating the impact of fluctuation from the level of IOP may be challenging because of the intimate relationship between

these two variables. IOP fluctuation is known to be positively correlated with mean IOP. In a retrospective study performed on non-human primates of experimental glaucoma, Gardiner and colleagues¹⁰ used the coefficient of variation (SD IOP divided by mean IOP) to remove the relationship between these two variables. In our cohort, the coefficient of variation reversed the association with mean IOP values, leading to a negative relationship between IOP fluctuation and mean IOP. The explanation for this is likely that there are two components of variability (measurement error and true IOP fluctuation), one of which (true fluctuation) is related to mean IOP and the other (measurement error) is not.¹⁴ Dividing the measurement error by the mean IOP induces the negative association. The method of normalization used in our study likely respects both the increased fluctuations at higher mean IOP and constant measurement errors. Fourth, IOP-related metrics tend to be highly correlated because they are related to the same original quantity. Modeling highly correlated variables may lead to a statistical issue called multicollinearity. In the presence of multicollinearity, regression models may become inefficient with loss of statistical power, greater computation inaccuracy, unstable estimates, and high variance.¹⁵ Various methods have been proposed to deal with multicollinearity. One or more highly collinear covariates may be omitted from the regression model, which may cause information loss. Ridge regression, a form of penalized linear regression, is another popular method to handle multicollinearity; however, it produces biased estimates and is better suited for predictive rather than explanatory models.¹⁶ In our study, we addressed the issue of multicollinearity with PCA, which creates a new set of orthogonal linear combinations of the original variables (PCs), by definition perfectly uncorrelated to each other.¹⁷ In this study, we used PCA to obtain a maximally informative combined metric of IOP control. Fifth,

clinicians are more likely to escalate treatment in progressing patients, inducing IOP fluctuation. This may be easily overlooked in retrospective cohort studies and even in prospective studies if countermeasures are not adopted. The findings of previous studies have been greatly questioned because of the possible bias caused by medical and surgical treatment escalation. Our study is not vulnerable to the potential confounding effect of treatment escalation as patients in the UKGTS took either latanoprost or placebo for their entire study period. In addition, our study is in the unique position to elucidate the role of IOP fluctuation on glaucomatous progression in untreated patients.

The relationship between IOP fluctuation and glaucomatous progression remains highly controversial, with contrasting results reported in the literature. Comparisons of results from different studies, including ours, should be done with caution because of heterogeneity in study populations, designs, definitions of fluctuation and progression, and statistical analysis. Most of the previous studies focused on long-term (intervisit) IOP fluctuation, which is the most accessible fluctuation metric to obtain as it can be estimated from single IOP measurements from multiple visits. Our study did not find any relationship between long-term IOP fluctuation and VF progression rates. Bengtsson et al.⁵ conducted a post-hoc analysis from the Early Manifest Glaucoma Trial (EMGT); they found that mean IOP was a strong predictor of glaucoma progression, while IOP fluctuation was not. EMGT and UKGTS share many similarities, including the mild disease stage, type of treatment (i.e., nonsurgical intervention), and mean IOP values. An observational study by Medeiros et al.¹⁸ investigated whether IOP fluctuations were associated with the risk of conversion from ocular hypertensive to glaucoma and found that mean IOP, but not long-term IOP fluctuation, was associated with glaucoma

development. Other studies found contrasting results, showing a positive association between long-term IOP fluctuation and VF progression. In a post-hoc analysis of the Advanced Glaucoma Intervention Study (AGIS), Nouri-Mahdavi and colleagues⁹ found that long-term IOP fluctuation was an independent risk factor for glaucoma progression, while mean IOP was not. The results of this study were criticized because the authors analyzed the entire available follow-up, including time points after treatment escalation. Further intervention, either in the form of trabeculectomy or laser trabeculoplasty as per AGIS protocol, might have been itself a cause of clinician-induced increased fluctuation in patients at high risk of progression. In a subsequent post-hoc analysis of the AGIS, Caprioli and Coleman⁸ investigated the relationship between long-term IOP fluctuation and VF progression, excluding those patients having multiple interventions; they found that long-term IOP fluctuations was significantly associated with VF progression in patients with low mean IOP, but not in those with high IOP. A post-hoc analysis from the Collaborative Initial Glaucoma Treatment Study (CIGTS)⁶ examined the role of various IOP parameters on VF progression and found that long-term IOP fluctuation and peak IOP were associated with VF progression, while mean IOP was not.

The literature on the role of diurnal (or diurnal-nocturnal) IOP fluctuation is scarce, of lower quality, and with conflicting reports. In the Malmö Ocular Hypertension study,¹⁹ diurnal IOP fluctuation was not an independent risk factors for the development of glaucoma; conversely, mean IOP was associated with the incidence of glaucomatous visual field loss in patients with OHT. Our study did not find an association between diurnal IOP fluctuation and the rate of glaucomatous progression in any of the models, corroborating the findings of the Malmö Ocular Hypertension study. In a secondary analysis from a Swedish clinical trial

randomizing patients to either pilocarpine or argon laser trabeculoplasty, Bergea et al.²⁰ investigated the relationship between visual field progression and different IOP variables, and they found that both mean IOP and diurnal IOP fluctuation were associated with visual field progression. That study, however, had several limitations, including the small sample size (76 eyes), high proportion of pseudoexfoliation glaucoma (72%), and the use of range IOP as a measure of fluctuation, which is vulnerable to outlier and highly related to peak IOP. A retrospective study by Matlach and colleagues²¹ assessed the impact of long-term and diurnal-nocturnal IOP fluctuation on glaucoma progression in a cohort of 120 glaucoma patients randomly selected from a tertiary referral center; they found that diurnal-nocturnal IOP fluctuation was associated with glaucoma progression, while long-term IOP fluctuation and mean IOP were not. A retrospective study by Kim et al.²² found similar results in a cohort of NTG patients, with higher diurnal IOP fluctuations and disc hemorrhages being associated with higher hazard of visual field progression. Both these studies are limited by their retrospective nature, making them vulnerable to potential confounders and selection bias. Also, these studies did not employ any statistical method to mitigate multicollinearity.

Besides including these two established measures of IOP fluctuation, we also investigated the role of very short-term fluctuation, as measured by the mean ocular pulse amplitude (OPA) over follow-up. OPA is calculated as the difference between systolic and diastolic IOP, as measured by the Pascal dynamic contour tonometer, and informs on how IOP varies across the cardiac cycle, secondary to the pulsatile influx/efflux of blood volume into the eye (mainly to choroid). Ocular pulse may be determined by various ocular and systemic factors, including ocular tissue rigidity,²³⁻²⁵ axial length,²⁶ IOP,^{23, 27} blood pressure pulse amplitude,^{28, 29} left ventricular

ejection time,³⁰ heart rate,^{31, 32} and conditions influencing ocular perfusion (e.g., carotid artery stenosis, tight encircling band).^{33, 34} To the best of our knowledge, there are currently no clinical studies investigating the role of OPA (or any metric for very short IOP fluctuation) on glaucoma progression. We found that higher OPA was significantly associated with faster pointwise rates of progression in the placebo group. Reasons for this finding are speculative. This association may result from an effect of the OPA itself or be related to one or more of its determinants. Animal studies have shown that acute IOP elevation may induce structural optic nerve head deformations and functional electrophysiological changes. Hence, multiple transient IOP spikes may cause faster glaucoma progression in vulnerable eyes. This explanation seems unlikely as these studies investigated large IOP changes, much larger than those measured with OPA. Higher OPA is associated with increased scleral rigidity and stiffer ocular tissues, which may be less compliant to IOP changes, causing larger stress within the lamina cribrosa secondary to IOP elevation.^{35, 36} In a simulation study based on finite element analysis reconstructing a healthy eye model, Jin et al.³⁶ found that stiffer sclera was associated with higher OPA, larger ONH deformation, and increased shearing forces to neural axons of the neuroretinal rim. OPA has been proposed as a surrogate measure for hemodynamics, being influenced by the arterial pulse pressure, heart rate, and left-ventricular ejection time. Low diastolic blood pressure, vascular dysregulation and optic nerve hypoperfusion have been associated with glaucoma progression, especially in some phenotypes of open-angle glaucoma. However, one would expect an opposite association to that found in this study, as lower OPA has been associated with lower ocular blood supply. On the other hand, larger arterial pulse pressure is associated with systemic hypertension, which may lead to vascular

damage. So, high OPA might be a surrogate for hypertensive vascular damage, and previous studies^{37, 38} have shown that high blood pressure may be a risk factors for primary open-angle glaucoma.

Our study confirms the importance of elevated IOP on glaucoma progression. PC1, which combined information from various IOP parameters (i.e., mean IOP, peak IOP, baseline IOP, peak phasing IOP, and supine IOP), was consistently associated with the rate of visual field progression in the placebo group. On the other hand, such a relationship was significant in the treatment group only for the rates of the fastest five visual field locations, but not for global rates of change. The progression rate of the treatment arm was extremely slow during the trial duration, and the signal from a few progressing locations may be obscured by the overall stability of most test locations. Comparative studies^{39, 40} have shown that pointwise methods (especially those considering only locations with significant deterioration) have higher sensitivity and require less time to detect progression than those based on global indices or all test locations. Our study does not provide any information on which IOP metric is the most important for disease progression; this is arduous to tackle because of the intimate relationship among these variables. De Moraes and colleagues² evaluated the effect of mean IOP, peak IOP, and SD IOP in a large retrospective cohort of glaucoma patients under clinical care; they found that all these variables were associated with disease progression in the univariable analysis, but only peak IOP was significantly associated with VF progression in the multivariable model. However, mean IOP and peak IOP are highly correlated, and a multivariable model containing both variables would likely suffer from multicollinearity. Treatment modifications highly influence mean IOP and SD IOP in

real-world settings; although the occurrence of glaucoma surgery during follow-up was taken into consideration, medical treatment escalation was not.

We also investigated the impact of non-IOP and other ocular factors on glaucomatous progression rates, including age, CCT, and corneal hysteresis. The evidence for role of CCT as a risk factor for glaucoma progression is often misunderstood. A thinner cornea causes artifacts in applanation tonometry, with underestimation of the true IOP.⁴¹ Alternatively, corneal thickness may serve as a biomarker of the biomechanical properties of the lamina cribrosa and peripapillary sclera, providing insights into the vulnerability of the optic nerve to increased IOP.⁴² An experimental study by Wells and colleagues⁴³ investigated whether CCT was associated with optic disc compliance after inducing acute IOP rise and found no significant association, indicating that CCT may not reflect ocular biomechanics. In our cohort, thinner CCT was associated with faster progression rates in some multivariable models (which included IOP metrics), while it did not show significance in any of the univariable models. This suggests that CCT alone is not directly associated with glaucoma progression: rather, it becomes statistically significant when measured IOP is included in the model due to the effect of CCT on measured IOP. Other studies, including the Early Manifest Glaucoma Treatment (EMGT)⁴⁴ and the Los Angeles Latino Eye Study (LALES),⁴⁵ found similar finding, associating thin CCT with conversion to glaucoma and incident glaucoma in multivariable models, but not in univariable models. Khawaja and Jansonius⁴⁶ performed a simulation study that mimicked datasets similar to the LALES and Ocular Hypertensive Treatment Study so that IOP, but not CCT, was not associated with glaucoma risk. Consistent with our findings and those from other studies, they found that CCT was not associated with the risk of glaucoma in the univariable model, but a spurious

association between CCT and glaucoma appeared when measured IOP was added to the model.

Although previous studies⁴⁷⁻⁴⁹ have shown a relationship between corneal hysteresis and visual field progression rates, we were not able to confirm such association in our cohort. In any given eye, corneal hysteresis is inversely related to IOP. Therefore, low corneal hysteresis may reflect high IOP, which is an established risk factors for faster glaucoma progression. Also, corneal hysteresis is directly related to corneal stiffness and thickness. Hence, IOP might have underestimated in patients with low corneal hysteresis, with consequent undertreatment leading to faster progression.

Many studies have reported an association between older age and faster progression rates.^{1, 44, 50, 51} In our study, older age was associated with faster MD (but not pointwise) progression rates in the latanoprost group but not in the placebo group. Ageing causes the lamina cribrosa to become stiffer and less compliant, potentially reducing its ability and that of peripapillary sclera to comply with IOP changes. Girard and colleagues³⁵ investigated the age-related biomechanical differences in monkey posterior sclera and found that older animals had higher tensile stress secondary to IOP elevation than younger ones. As tensile stress increased non-linearly with IOP rise, the impact of ageing should theoretically be more pronounced in patients with higher mean IOP; however, we found that older age was associated with worse progression rates in the treatment arm, which had lower mean IOP than the placebo arm. This finding is in agreement with a large retrospective cohort study by De Moraes and colleagues², reporting that older age was independently associated with glaucomatous VF progression only in patients with lower mean IOP. Similar findings were found in the JAMDIG study, a large

retrospective study conducted in Japanese patients with fairly low mean IOP values.⁵⁰ An explanation to these findings may be that the impact of non-IOP factors, including age, becomes more important only after substantially lowering the IOP.

This study has limitations. This was a planned secondary analysis based on the UKGTS dataset and the number of subjects and the duration of follow-up may not provide enough statistical power to identify a meaningful relationship between IOP fluctuation and visual field progression, especially in the treatment arm, where progression rates were extremely slow over the study period. The study cohort included treatment-naïve primary open-glaucoma patients, mainly of European descent and with early glaucomatous damage. Some authors¹¹ have hypothesized that the effect of IOP fluctuation on the rates of visual progression might vary as a function of disease stage, mean IOP, glaucoma subtype, ethnicity, and treatment modality (medical vs surgical intervention); hence, the results of this study may be not entirely generalizable to other populations. Nevertheless, the results of this study are in agreement with those from the EMGT analysis.⁵ The diurnal IOP fluctuation calculation was based on five measurements obtained during the morning and afternoon, and this study provides only IOP snapshots across the day and no information on IOP fluctuation outside office hours. Although we used clinically relevant definitions of IOP fluctuation, these measurements may not adequately characterize short-term IOP variability. Diurnal phasing has been shown to be poorly reproducible, indicating that single-day IOP measurements may not be sufficient to accurately assess short-term fluctuations.⁵²⁻⁵⁵ Our findings are consistent with existing literature in this field. A comparison between the two available diurnal IOP curves revealed that the 95% limits of agreement were around 4 mmHg, aligning closely with the most pronounced fluctuation extremes observed in this dataset

(Figure S15). Differences between diurnal IOP fluctuation calculated in the first and last post-randomization visits were random and approximate a normal distribution (Figure S16). Several studies^{56, 57} have documented a nocturnal peak in IOP, primarily attributed to an increase in episcleral venous pressure when the body is in a horizontal position. Although our study did not include night-time IOP measurements, we did record IOP in a supine position, which is recognized as a reasonable proxy for estimating nocturnal peak levels.⁵⁸ While devices for home IOP monitoring^{59, 60} or continuous IOP tracking^{61, 62} have been introduced, they were not collected in the UKGTS study and are generally reserved for research rather than routine clinical use. Although the methodology employed in this study may not capture the entire spectrum or precise patterns of IOP fluctuations, we adopted a clinically relevant approach to defining diurnal IOP fluctuation.

In conclusion, this study finds no evidence to support that either diurnal ~~and or~~ long-term IOP fluctuation, defined in a clinically relevant manner, are independent factors for glaucoma progression. Other aspects of IOP, such as mean IOP and peak IOP, may be more informative. Higher OPA may be an independent factor for faster glaucoma progression.

600 **ACKNOWLEDGMENTS**

601 The trial sponsor was Moorfields Eye Hospital NHS Foundation Trust. The
602 principal funding was through an unrestricted investigator-initiated research grant
603 from Pfizer, with supplementary funding from the UK's NIHR Biomedical Research
604 Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
605 Ophthalmology, London, UK. Equipment loans were made by Heidelberg
606 Engineering, Carl Zeiss Meditec and Optovue (Optovue, Fremont, CA, USA). DFG-
607 H's chair at UCL is supported by funding from the nonprofit association Glaucoma
608 UK.

609 **Declaration of Generative AI and AI-assisted technologies in the writing**
610 **process**

611

612 During the preparation of this work the authors used chatGPT3.5 in order to improve
613 readability and language of the manuscript. After using this tool/service, the authors
614 reviewed and edited the content as needed and take full responsibility for the content
615 of the publication.

REFERENCES

1. Kim JH, Rabiolo A, Morales E, et al. Risk Factors for Fast Visual Field Progression in Glaucoma. *Am J Ophthalmol* 2019;207:268-78.
2. De Moraes CG, Juthani VJ, Liebmann JM, et al. Risk factors for visual field progression in treated glaucoma. *Arch Ophthalmol* 2011;129(5):562-8.
3. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet* 2015;385(9975):1295-304.
4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol* 2002;120(6):714-20; discussion 829-30.
5. Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(2):205-9.
6. Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2011;118(9):1766-73.
7. Lee PP, Walt JW, Rosenblatt LC, et al. Association between intraocular pressure variation and glaucoma progression: data from a United States chart review. *Am J Ophthalmol* 2007;144(6):901-7.
8. Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. *Ophthalmology* 2008;115(7):1123-9 e3.

- 639 9. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for
 640 glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.
 641 Ophthalmology 2004;111(9):1627-35.
- 642 10. Gardiner SK, Fortune B, Wang L, et al. Intraocular pressure magnitude and
 643 variability as predictors of rates of structural change in non-human primate
 644 experimental glaucoma. Exp Eye Res 2012;103:1-8.
- 645 11. Kim JH, Caprioli J. Intraocular Pressure Fluctuation: Is It Important? J
 646 Ophthalmic Vis Res 2018;13(2):170-4.
- 647 12. Lascaratos G, Garway-Heath DF, Burton R, et al. The United Kingdom
 648 Glaucoma Treatment Study: a multicenter, randomized, double-masked, placebo-
 649 controlled trial: baseline characteristics. Ophthalmology 2013;120(12):2540-5.
- 650 13. Garway-Heath DF, Lascaratos G, Bunce C, et al. The United Kingdom
 651 Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical
 652 trial: design and methodology. Ophthalmology 2013;120(1):68-76.
- 653 14. Kotecha A, White E, Schlottmann PG, Garway-Heath DF. Intraocular pressure
 654 measurement precision with the Goldmann applanation, dynamic contour, and ocular
 655 response analyzer tonometers. Ophthalmology 2010;117(4):730-7.
- 656 15. Gunst RF. Regression analysis with multicollinear predictor variables:
 657 definition, detection, and effects. Communications in Statistics - Theory and Methods
 658 1983;12(19):2217-60.
- 659 16. Mahajan V, Jain AK, Bergier M. Parameter Estimation in Marketing Models in
 660 the Presence of Multicollinearity: An Application of Ridge Regression. Journal of
 661 Marketing Research 1977;14(4):586-91.
- 662 17. Morzuch BJ, Ruark GA. Principal Components Regression to Mitigate the
 663 Effects of Multicollinearity. Forest Science 1991;37(1):191-9.

- 664 18. Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure
665 fluctuations and risk of conversion from ocular hypertension to glaucoma.
666 *Ophthalmology* 2008;115(6):934-40.
- 667 19. Bengtsson B, Heijl A. Diurnal IOP fluctuation: not an independent risk factor
668 for glaucomatous visual field loss in high-risk ocular hypertension. *Graefes Arch Clin*
669 *Exp Ophthalmol* 2005;243(6):513-8.
- 670 20. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on
671 visual fields in open-angle glaucoma. *Ophthalmology* 1999;106(5):997-1004;
672 discussion -5.
- 673 21. Matlach J, Bender S, Konig J, et al. Investigation of intraocular pressure
674 fluctuation as a risk factor of glaucoma progression. *Clin Ophthalmol* 2019;13:9-16.
- 675 22. Kim SH, Lee EJ, Han JC, et al. The Effect of Diurnal Fluctuation in Intraocular
676 Pressure on the Evaluation of Risk Factors of Progression in Normal Tension
677 Glaucoma. *PLoS One* 2016;11(10):e0164876.
- 678 23. Dastiridou AI, Ginis HS, De Brouwere D, et al. Ocular rigidity, ocular pulse
679 amplitude, and pulsatile ocular blood flow: the effect of intraocular pressure. *Invest*
680 *Ophthalmol Vis Sci* 2009;50(12):5718-22.
- 681 24. Ma Y, Moroi SE, Roberts CJ. Non-invasive Clinical Measurement of Ocular
682 Rigidity and Comparison to Biomechanical and Morphological Parameters in
683 Glaucomatous and Healthy Subjects. *Front Med (Lausanne)* 2021;8:701997.
- 684 25. Markert JE, Turner DC, Jasien JV, et al. Ocular Pulse Amplitude Correlates
685 With Ocular Rigidity at Native IOP Despite the Variability in Intraocular Pulse Volume
686 With Each Heartbeat. *Transl Vis Sci Technol* 2022;11(9):6.

- 687 26. Dastiridou AI, Ginis H, Tsilimbaris M, et al. Ocular rigidity, ocular pulse
688 amplitude, and pulsatile ocular blood flow: the effect of axial length. *Invest*
689 *Ophthalmol Vis Sci* 2013;54(3):2087-92.
- 690 27. Choi J, Lee J, Park SB, et al. Factors affecting ocular pulse amplitude in eyes
691 with open angle glaucoma and glaucoma-suspect eyes. *Acta Ophthalmol*
692 2012;90(6):552-8.
- 693 28. Abegao Pinto L, Vandewalle E, Willekens K, et al. Ocular pulse amplitude and
694 Doppler waveform analysis in glaucoma patients. *Acta Ophthalmol* 2014;92(4):e280-
695 5.
- 696 29. Kim YJ, Lee KS, Lee JR, et al. Ocular pulse amplitude as a dynamic
697 parameter and its relationship with 24-h intraocular pressure and blood pressure in
698 glaucoma. *Exp Eye Res* 2013;115:65-72.
- 699 30. Grieshaber MC, Katamay R, Gugleta K, et al. Relationship between ocular
700 pulse amplitude and systemic blood pressure measurements. *Acta Ophthalmol*
701 2009;87(3):329-34.
- 702 31. Trew DR, James CB, Thomas SH, et al. Factors influencing the ocular pulse--
703 the heart rate. *Graefes Arch Clin Exp Ophthalmol* 1991;229(6):553-6.
- 704 32. Gekkieva M, Orgul S, Gherghel D, et al. The influence of sex difference in
705 measurements with the Langham Ocular Blood Flow System. *Jpn J Ophthalmol*
706 2001;45(5):528-32.
- 707 33. Knecht PB, Menghini M, Bachmann LM, et al. The ocular pulse amplitude as
708 a noninvasive parameter for carotid artery stenosis screening: a test accuracy study.
709 *Ophthalmology* 2012;119(6):1244-9.
- 710 34. Lincoff H, Stopa M, Kreissig I, et al. Cutting the encircling band. *Retina*
711 2006;26(6):650-4.

- 712 35. Girard MJ, Suh JK, Bottlang M, et al. Scleral biomechanics in the aging
713 monkey eye. *Invest Ophthalmol Vis Sci* 2009;50(11):5226-37.
- 714 36. Jin Y, Wang X, Zhang L, et al. Modeling the Origin of the Ocular Pulse and Its
715 Impact on the Optic Nerve Head. *Invest Ophthalmol Vis Sci* 2018;59(10):3997-4010.
- 716 37. Bae HW, Lee N, Lee HS, et al. Systemic hypertension as a risk factor for
717 open-angle glaucoma: a meta-analysis of population-based studies. *PLoS One*
718 2014;9(9):e108226.
- 719 38. Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and
720 primary open-angle glaucoma: a meta-analysis. *Am J Ophthalmol* 2014;158(3):615-
721 27 e9.
- 722 39. Rabiolo A, Morales E, Mohamed L, et al. Comparison of Methods to Detect
723 and Measure Glaucomatous Visual Field Progression. *Transl Vis Sci Technol*
724 2019;8(5):2.
- 725 40. Mayama C, Araie M, Suzuki Y, et al. Statistical evaluation of the diagnostic
726 accuracy of methods used to determine the progression of visual field defects in
727 glaucoma. *Ophthalmology* 2004;111(11):2117-25.
- 728 41. Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on
729 applanation tonometry. *Am J Ophthalmol* 1993;115(5):592-6.
- 730 42. Lesk MR, Hafez AS, Descovich D. Relationship between central corneal
731 thickness and changes of optic nerve head topography and blood flow after
732 intraocular pressure reduction in open-angle glaucoma and ocular hypertension.
733 *Arch Ophthalmol* 2006;124(11):1568-72.
- 734 43. Wells AP, Garway-Heath DF, Poostchi A, et al. Corneal hysteresis but not
735 corneal thickness correlates with optic nerve surface compliance in glaucoma
736 patients. *Invest Ophthalmol Vis Sci* 2008;49(8):3262-8.

- 737 44. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the
738 early manifest glaucoma trial. *Ophthalmology* 2007;114(11):1965-72.
- 739 45. Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the
740 development of open-angle glaucoma in a population: the Los Angeles Latino Eye
741 Study. *Ophthalmology* 2012;119(11):2245-53.
- 742 46. Khawaja AP, Jansonius NM. Potential for Collider Bias in Studies Examining
743 the Association of Central Corneal Thickness With Glaucoma. *Invest Ophthalmol Vis*
744 *Sci* 2022;63(12):3.
- 745 47. Medeiros FA, Meira-Freitas D, Lisboa R, et al. Corneal hysteresis as a risk
746 factor for glaucoma progression: a prospective longitudinal study. *Ophthalmology*
747 2013;120(8):1533-40.
- 748 48. Chan E, Yeh K, Moghimi S, et al. Changes in Corneal Biomechanics and
749 Glaucomatous Visual Field Loss. *J Glaucoma* 2021;30(5):e246-e51.
- 750 49. Kamalipour A, Moghimi S, Eslani M, et al. A Prospective Longitudinal Study to
751 Investigate Corneal Hysteresis as a Risk Factor of Central Visual Field Progression
752 in Glaucoma. *Am J Ophthalmol* 2022;240:159-69.
- 753 50. Fujino Y, Asaoka R, Murata H, et al. Evaluation of Glaucoma Progression in
754 Large-Scale Clinical Data: The Japanese Archive of Multicentral Databases in
755 Glaucoma (JAMDIG). *Invest Ophthalmol Vis Sci* 2016;57(4):2012-20.
- 756 51. Bommakanti N, De Moraes CG, Boland MV, et al. Baseline Age and Mean
757 Deviation Affect the Rate of Glaucomatous Vision Loss. *J Glaucoma* 2020;29(1):31-
758 8.
- 759 52. Aptel F, Lesoin A, Chiquet C, et al. Long-term reproducibility of diurnal
760 intraocular pressure patterns in patients with glaucoma. *Ophthalmology*
761 2014;121(10):1998-2003.

- 762 53. Realini T, Weinreb RN, Wisniewski S. Short-term repeatability of diurnal
763 intraocular pressure patterns in glaucomatous individuals. *Ophthalmology*
764 2011;118(1):47-51.
- 765 54. Realini T, Weinreb RN, Wisniewski SR. Diurnal intraocular pressure patterns
766 are not repeatable in the short term in healthy individuals. *Ophthalmology*
767 2010;117(9):1700-4.
- 768 55. Hatanaka M, Babic M, Susanna R, Jr. Reproducibility of the mean, fluctuation,
769 and IOP peak in the diurnal tension curve. *J Glaucoma* 2013;22(5):390-2.
- 770 56. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular
771 pressure in young adults. *Invest Ophthalmol Vis Sci* 1998;39(13):2707-12.
- 772 57. Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular
773 pressure pattern associated with early glaucomatous changes. *Invest Ophthalmol*
774 *Vis Sci* 2003;44(4):1586-90.
- 775 58. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak
776 nocturnal intraocular pressures in healthy subjects and glaucoma patients. *Am J*
777 *Ophthalmol* 2005;139(2):320-4.
- 778 59. Sakamoto M, Kanamori A, Fujihara M, et al. Assessment of IcareONE
779 rebound tonometer for self-measuring intraocular pressure. *Acta Ophthalmol*
780 2014;92(3):243-8.
- 781 60. Halkiadakis I, Stratos A, Stergiopoulos G, et al. Evaluation of the Icare-ONE
782 rebound tonometer as a self-measuring intraocular pressure device in normal
783 subjects. *Graefes Arch Clin Exp Ophthalmol* 2012;250(8):1207-11.
- 784 61. Mansouri K, Weinreb RN, Liu JH. Efficacy of a contact lens sensor for
785 monitoring 24-h intraocular pressure related patterns. *PLoS One*
786 2015;10(5):e0125530.

787 62. Marando CM, Mansouri K, Kahook MY, Seibold LK. Tolerability and
788 Functionality of a Wireless 24-Hour Ocular Telemetry Sensor in African American
789 Glaucoma Patients. J Glaucoma 2019;28(2):119-24.
790

FIGURE LEGENDS

Figure 5. Boxplots comparing the various IOP metrics in the placebo and treatment groups. IOP: intraocular pressure; MD: mean deviation; OPA: ocular pulse amplitude; SD: standard deviation.

Figure 6. Density plots for the distribution of MD (**left panel**) and pointwise (**right panel**) rates of progression in the placebo and latanoprost groups. MD: mean deviation. PLR: pointwise linear rates.

Figure 7. Forest plots for factors associated with the MD rates of progression in the placebo (**left panel**) and treatment (**right panel**) group. Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. Combined IOP metrics PC1 is a unitless variable, which combines fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; MD: mean deviation; OPA: ocular pulse amplitude; PC1: principal component 1.

Figure 8. Forest plots for factors associated with the pointwise rates of progression in the placebo (**left panel**) and treatment (**right panel**) group. Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. Combined IOP metrics PC1 is a unitless variable, which combines fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component

816 Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular
817 pressure; OPA: ocular pulse amplitude; PC1: principal component 1; PLR: pointwise
818 linear rates.

819

820 **Figure 9.** Forest plots for factors associated with the pointwise rates of progression
821 of the five fastest locations in the placebo **(left panel)** and treatment **(right panel)**
822 group. Dots and bars indicate point estimates and 95% confidence intervals,
823 respectively. Estimates are intended for 1-unit increase, unless specified otherwise.
824 Combined IOP metrics PC1 is an unitless variable, which combines fluctuation
825 unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak
826 phasing IOP) through Principal Component Analysis. CCT: central corneal thickness;
827 CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude;
828 PC1: principal component 1; PLR: pointwise linear rates.

- Manuscript –

Relationship between intraocular pressure fluctuation and visual field progression rates in the United Kingdom Glaucoma Treatment Study

Authors: Alessandro Rabiolo, MD, FEBO¹⁻³; Giovanni Montesano, MD^{1,4}; David P Crabb PhD⁴; David F Garway-Heath, MD, FRCOphth¹, on behalf of the United Kingdom Glaucoma Treatment Study Investigators

Authors affiliation:

- (1)** NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom.
- (2)** Ophthalmology Unit, University Hospital Maggiore della Carità, Novara, Italy.
- (3)** Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", Novara, Italy.
- (4)** Optometry and Visual Sciences, City University of London, London, London, United Kingdom.

Corresponding author: Prof David F Garway-Heath, Moorfields Eye Hospital, London EC1V 2PD, UK; d.garwayheath@nhs.net

Short title: IOP fluctuation and glaucoma progression rates in the UKGTS

Conflict of Interest: None of the authors has any competing interest.

Financial Disclosures: Alessandro Rabiolo has received support for attending meetings from Thea Farma spa, Bausch + Lomb, and Visufarma spa. Giovanni Montesano has received consulting fees from Alcon Inc, CenterVue-Icare, and

Omikron spa, has received speaker fees and support for attending meetings from Omikron spa, and has leadership role in the Relayer Ltd. David Crabb:

Consultant/Contractor for Allergan, Apellis Pharmaceuticals, CenterVue-Icare, Thea, Roche; non-remunerative relationship with Santen, Medisoft; Financial Support from Santen, AbbVie, Apellis Pharmaceuticals, CenterVue-Icare. David Garway-Heath has the following disclosure: Consultant/Contractor for AbbVie, Genentech, Janssen, Novartis, Omikron, Roche, Santen; Financial Support from Alcon Research Institute, Janssen, Santen.

Financial support: The trial sponsor was Moorfields Eye Hospital NHS Foundation Trust. The principal funding was through an unrestricted investigator-initiated research grant from Pfizer, with supplementary funding from the UK's NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. Equipment loans were made by Heidelberg Engineering, Carl Zeiss Meditec and Optovue (Optovue, Fremont, CA, USA). DFG-H's chair at UCL is supported by funding from the nonprofit association Glaucoma UK.

Presented at: Association for Research in Vision and Ophthalmology Annual Meeting, May 2022, Denver, Canada; 15th European Glaucoma Society Congress, June 2022, Athens, Greece.

ABSTRACT

Purpose. To investigate whether intraocular pressure (IOP) fluctuation is independently associated with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study.

Design. Randomized, double-masked, placebo-controlled multicenter trial.

Participants: Participants with ≥ 5 VFs (213 placebo, 217 treatment).

Methods. Associations between IOP metrics and the VF progression rates (mean deviation (MD) and five fastest locations) were assessed with linear mixed models.

Fluctuation variables were mean ocular pulse amplitude (OPA), standard deviation (SD) of diurnal IOP (diurnal fluctuation), and SD of IOP at all visits (long-term

fluctuation). Fluctuation values were normalized for mean IOP to make them

independent from mean IOP. Correlated non-fluctuation IOP metrics (baseline, peak,

mean, supine and peak phasing IOP) were combined with principal component

analysis (PCA), and principal component 1 (PC1) was included as a covariate.

Interactions between covariates and time from baseline modelled the effect of the

variables on VF rates. IOP was measured with Goldmann applanation tonometry and

OPA with Pascal tonometry. Analyses were conducted separately in the two

treatment arms.

Main Outcome Measures. Associations between IOP fluctuation metrics and rates of MD and five fastest test locations.

Results. In the placebo arm, only PC1 was significantly associated with the MD rate (estimate [standard error (SE)]: -0.19 [0.04] dB/year, $p < 0.001$), while normalized IOP

fluctuation metrics were not. No variable was significantly associated with MD rates

in the treatment arm. For the fastest five locations in the placebo group, PC1

(estimate [SE]: -0.58 [0.16] dB/year, $p < 0.001$), CCT (estimate [standard error (SE)]:

25 0.26 [0.10] dB/year for 10 μ m thicker, $p=0.01$) and normalized OPA (estimate [SE]: -
26 3.50 [1.04] dB/year, $p=0.001$) were associated with rates of progression; normalized
27 diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1
28 (estimate [SE]: -0.27 [0.12] dB/year, $p=0.028$) was associated with the rates of
29 progression.

30 **Conclusions.** There is no evidence to support that either diurnal or long-term IOP
31 fluctuation, as measured in clinical practice, are independent factors for glaucoma
32 progression; other aspects of IOP, including mean IOP and peak IOP, may be more
33 informative. OPA may be an independent factor for faster glaucoma progression.

34

35 **Keywords:** visual field progression; ocular pulse amplitude; risk factors; linear
36 mixed models.

INTRODUCTION

Intraocular pressure (IOP) is an established risk factor for glaucoma progression, and lowering IOP is currently the only available treatment to slow the disease progression.¹⁻⁴ Longitudinal measurement of IOP is crucial in evaluating glaucoma patients, estimating their risk of developing progressive glaucomatous damage, and assessing their response to treatment.

IOP is subject to fluctuations over time. Several IOP-derived parameters are commonly used in clinical practice and research to summarize the behavior of IOP, including mean IOP (average of IOP over multiple visits), peak IOP (highest IOP reading over follow-up), and IOP fluctuation (standard deviation [SD] or range IOP over time). Many studies have shown that mean IOP and peak IOP are independently associated with glaucoma progression;^{1, 2, 5, 6} on the other hand, the exact role of IOP fluctuation is still debated, with discordant results reported in the literature.⁵⁻¹⁰ Elucidating the role of IOP fluctuation is difficult for several reasons. IOP fluctuation is tightly correlated with other IOP-related metrics (e.g., mean IOP), making it difficult to isolate its role as an independent factor. IOP fluctuation may be artificially increased by escalating treatment in patients with suspect progression. The effect of IOP fluctuation may not be uniform, varying as a function of the disease stage, treatment status, mean IOP values, and definition of fluctuation.¹¹

This planned secondary analysis of the United Kingdom Glaucoma Treatment Study (UKGTS) randomized controlled trial aimed to evaluate whether IOP fluctuation, as assessed by ocular pulse amplitude (OPA), diurnal variation and between-visit variation, is independently associated with the rate of visual field progression. The UKGTS is ideal for this purpose because there were no treatment

- 61 escalations artificially increasing IOP fluctuation, and the dataset allows evaluation of
- 62 IOP metrics in both untreated and treated glaucoma patients.

METHODS

Study Population and Procedures

This study was a planned secondary analysis of data from the UKGTS, which was a multicenter, randomized, triple-masked, placebo-controlled trial investigating the ability of Latanoprost, an IOP lowering medication, to preserve visual function in newly diagnosed open-angle glaucoma patients (trial registration number, ISRCTN96423140). The UKGTS and the subsequent analysis of anonymized data in this study complied with the tenets of the Declaration of Helsinki and were approved by local institutional review boards (Moorfields and Whittington Research Ethics Committee on June 1, 2006, ethics approval reference, 09/H0721/56). All patients provided written informed consent at the time of enrolment in the trial.

The UKGTS study protocol, baseline characteristics, and outcomes have been published elsewhere.^{3, 12, 13} Participants recruited in 10 ophthalmology institutions across the United Kingdom were randomized 1:1 to receive latanoprost 0.005% or placebo eye drops once in the evening in both eyes for 24 months or until meeting an endpoint. The UKGTS included patients ≥ 18 years of age and newly diagnosed treatment-naïve open-angle glaucoma, including primary open-angle and pseudoexfoliation glaucoma. Exclusion criteria were: advanced glaucoma, as defined by visual field mean deviation < -10 dB in the better eye or < -16 dB in the worse eye, mean baseline IOP ≥ 30 mmHg, Snellen best-corrected visual acuity (BCVA) $< 6/12$, and poor image quality (>40 μ m mean pixel height standard deviation) with the Heidelberg retina tomograph (Heidelberg Engineering, Heidelberg, Germany).

Potentially eligible participants underwent two pre-randomization visits. After meeting the study criteria and signing the written informed consent, participants were

randomized either to receive latanoprost 0.005% or placebo eye drops. Enrolled subjects underwent IOP measurement, VF, and imaging at eleven post-randomization visits over 24 months or until meeting an endpoint. Standard automated perimetry with the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) was performed with stimulus size III, Swedish Interactive Threshold Algorithm (SITA) standard strategy, and 24-2 grid. VF testing was performed at all 11 scheduled visits over 24 months, and tests were clustered (2 VFs on the same day) at baseline, 2 months, 16 months, 18 months, and 24 months. In this exploratory analysis, we included participants from the UKGTS with ≥ 5 reliable visual fields (VFs). Reliable VFs were defined as those with false positives less than 15%, while no limits for false negatives and fixation losses were applied. At the first post-randomization visit, the following demographic variables were collected: age, sex, ethnicity, family history of glaucoma, history of systemic diseases (i.e., systemic hypertension, cardiovascular disease, diabetes, heart attack, stroke, sleep apnea, migraine, Raynaud's phenomenon, vasospasm, angina, claudication), and smoking status. The following investigations were also performed: blood pressure measurements with the Omron M7 Blood Pressure Monitor (Matsusaka, Mie, Japan), weight, height, slit-lamp examination, refractive error measured either with an autorefractor or from spectacle focimetry (if not available, the spherical equivalent of the trial lens was used in the visual field test, based on participants' age), axial length measurement with the IOL Master (Carl Zeiss Meditec, Dublin, CA), and central corneal thickness (CCT) measured with an ultrasound pachymeter. We included one eye per patient; specifically, the eye with the worst baseline VF mean deviation (MD).

113 *IOP Metrics*

114 At all visits, IOP was measured with Goldmann applanation tonometry (GAT;
 115 Haag Streit, Koeniz, Switzerland), Pascal dynamic contour tonometry (Ziemer
 116 Ophthalmic Systems AG, Zurich, Switzerland), and the Ocular Response Analyzer
 117 (Reichert, Inc., Buffalo, NY). Diurnal GAT phasing with IOP measured every 2 hours
 118 from 9 am to 5 pm was performed at the first post-randomization and at the final visit.
 119 At the first post-randomization visit, supine IOP was measured with Perkins
 120 applanation tonometer.

121 The following IOP metrics were calculated and used for the analyses:

- 122 • Baseline pretreatment IOP, defined as the average of the IOP readings obtained
 123 in the two pre-randomization visits.
- 124 • Mean IOP, defined as the average of all post-randomization IOP readings.
- 125 • Peak IOP, defined as the highest IOP reading of all post-randomization IOP
 126 readings.
- 127 • Supine IOP, defined as the Perkins applanation tonometry IOP readings
 128 measured at the first post-randomization visit.
- 129 • Phasing peak IOP, defined as the highest IOP reading of the diurnal phasing
 130 performed at the first post-randomization visit.
- 131 • Diurnal IOP fluctuation, defined as the SD of IOP measurements obtained from
 132 the diurnal IOP phasing performed at the first post-randomization visit. Diurnal
 133 IOP fluctuation was also calculated using the IOP measurements from the last
 134 post-randomization visit.
- 135 • Long-term IOP fluctuation, defined as the SD of post-randomization IOP
 136 readings.

- Mean ocular pulse amplitude (OPA) from the Pascal Dynamic Contour tonometry. OPA was defined as the range of the pulse wave contour and provides a measure of how IOP fluctuates over cardiac cycle. We used the average of all post-randomization OPA values.

Statistical Analysis

We performed all statistical analyses with the open-source software R (R Foundation for Statistical Computing, Vienna, Austria). Variable distributions were inspected with histograms and quantile-quantile plots. We reported mean ($\pm$ Standard deviation [SD]) and median (interquartile range [IQR]) for Gaussian and non-Gaussian variables, respectively. We reported frequencies and proportions for discrete variables. Proportion and pattern of missing data were analyzed. All analyses were conducted with complete cases. All tests were 2-tailed, and p-values <0.05 were considered statistically significant.

Demographic and clinical characteristics between the two treatment groups were compared with t-test and chi-squared test for continuous and categorical variables, respectively. Agreement between diurnal IOP fluctuation calculated on the first and last post-randomization visit was investigated with Bland-Altman statistics. We also collected the timing of each IOP measurement and calculated the absolute differences from each measurement and the mean time of day for each patient's IOP measurements.

Linear models were used to evaluate the relationship between (i) mean IOP and long-term IOP fluctuation, (ii) mean IOP and long-term IOP fluctuation/mean IOP, (iii) mean diurnal IOP and diurnal IOP fluctuation, (iv) mean diurnal IOP and diurnal IOP

fluctuation/mean diurnal IOP, (v) mean OPA and mean IOP, and (vi) mean OPA/GAT IOP and mean IOP.

IOP fluctuation is known to be positively correlated with mean IOP. Additionally, measurement error can contribute to the variability in IOP measurements, potentially confounding true IOP fluctuation. To obtain a measure of IOP fluctuation which is independent from mean IOP, we performed a normalization of IOP fluctuation values. Specifically, we ran a linear regression of IOP fluctuation against mean IOP. We then divided the observed IOP fluctuation values by the corresponding predicted values. This process was applied distinctly for each fluctuation metric. For long-term fluctuation, we utilized the SD of all post-randomization IOP readings and their corresponding mean IOP values from all post-randomization readings. For diurnal fluctuation, we used the SD and mean IOP measurements from the diurnal IOP phasing conducted during the first post-randomization visit. For the OPA, we used the average of all post-randomization ORA values for each subject and their corresponding mean IOP across all available post-randomization visits. For OPA, we calculated the average of all post-randomization ORA values for each subject, alongside their corresponding mean IOP from all available post-randomization visits.

As shown in Figure S1, normalized IOP fluctuation was unrelated to mean IOP. Normalization was further performed on the two study arms separately, leading to almost identical results (data not shown). All analyses were conducted on both normalized and unnormalized IOP fluctuations values.

Linear mixed models with random slopes and random intercepts were used to estimate the rates of progression and investigate associations between the rate of visual field progression and variables of interest. Linear mixed models are an extension of traditional linear models, which can accommodate the repeated-

186 measure (e.g., multiple measurements from the same eye over time) and clustered
187 (multiple test locations from the same VF) nature of data. We first look at univariable
188 associations between the MD rate of change and each variable of interest. In all
189 models, the MD value at each visit was the outcome variable; the follow-up time in
190 years, the covariate of interest, and their interaction were the fixed effects; the eye
191 identification number and follow-up time were the random intercept and random
192 slope terms, respectively, to account for the repeated measure of data and for the
193 fact that different eyes may have different rates of progression over time. Interactions
194 between covariates and time from baseline modeled the variables' effect on the
195 progression rate. We then built multiple variable linear mixed models to account for
196 the impact of fluctuation metrics after adjusting for all other potentially confounding
197 factors, including other IOP metrics. Correlations among candidate covariates were
198 tested with a hierarchical cluster analysis based on the absolute value of Spearman
199 correlations (Figure S2). Some of the variables measuring the magnitude of IOP
200 elevation exhibited high correlations. Highly correlated variables are a source of
201 multicollinearity, causing unstable regression coefficients and large standard errors.
202 To address this issue, all correlated metrics measuring IOP (baseline IOP, peak IOP,
203 mean IOP, supine IOP, peak phasing IOP) were combined using Principal
204 Component Analysis (PCA). These variables had a |Spearman rho| of 0.50 or
205 greater. PCA extracts uncorrelated orthogonal vectors (Principal Components [PCs])
206 from multiple correlated variables. PCs are ranked, with the first PC (PC1) being the
207 one containing the largest amount of combined information from the correlated
208 variables. PCA was performed on standardized data, with zero mean and unit
209 variance. We inspected the PCA model with biplots and scree plots (Figure S3).
210 Scree plots were used to visualize the amount of variance explained by the various

Principal Components and to select the number of PCs to retain for subsequent analyses. PC1 was selected for further analyses, as it explained 81% of the overall variance in the PCA, and used as a fixed effect in the multivariable linear mixed models. The Interaction between PC1 and follow-up time modelled the effect of PC1 on visual field progression rates, as previously explained. PCA was also performed on the two study arms separately, leading to similar results (data not shown).

Similar analyses were run in a pointwise manner, including: (i) all 52 VF test locations of the 24-2 grid (after excluding the two locations corresponding to the blind spot), and (ii) the five fastest progressing locations for each study eye (which is conceptually similar to the event-based GPA analysis which identifies the 3 or more locations most different from baseline). Models conducted on the pointwise threshold sensitivity data had a nested random intercept with eye identification number over the test location number to account for the inclusion of multiple pointwise series from the same eye. All models were run separately in the placebo and treatment arms. Regression estimates along with their 95% confidence intervals (95% CIs) and p-values were reported.

RESULTS

Of the 461 participants with longitudinal data included in the primary UKGTS analysis, 31 were excluded because of an insufficient number of VFs. The remaining 430 (placebo arm: 213, treatment arm: 217) participants were included in this study. As shown in Figure S4, most variables had complete observations, with only a few variables having missing observations. Spherical equivalent, CCT, and supine IOP values were missing in 26 eyes (6%), 16 (3.7%), and 15 eyes (3.5%), respectively. Mean arterial pressure, body mass index, ethnicity, corneal hysteresis, peak and mean phasing IOP, and diurnal fluctuation were missing in less than 2% of patients. All other variables had no missing data.

Baseline characteristics of the UKGTS study population have been published elsewhere.^{3, 12} Table 1 illustrates the main demographic and clinical characteristics of the patient cohort. Patients in the treatment cohort had significantly longer follow-up time than those in the placebo cohort, with a median (IQR) of 1.9 (1.3 to 2.0) and 1.6 (1.0 to 2.0) years, respectively ($p=0.004$). The number of VFs was also significantly greater ($p=0.027$) in the treatment arm (median [IQR]: 15 [10-16]) than in the placebo arm (median [IQR]: 13 [10-16]). In the post-randomization study period, patients in the treatment arm showed higher mean corneal hysteresis than those in the placebo arm (mean [$\pm$ SD]: 9.4 [$\pm$ 1.6] vs. 8.9 [$\pm$ 1.6] mmHg, $p=0.003$). As shown in Figure 5, all post-randomization IOP metrics were significantly different between the two arms ($p<0.045$ or below), except for normalized diurnal IOP fluctuation ($p=0.89$) and normalized OPA ($p=0.93$). The median of the absolute differences from the mean time of day for each patient's IOP measurements was 1.1 hours, with an interquartile range (IQR) of 0.5 hours (30 minutes) to 2.0 hours.

252 *Global MD rate*

253 The distribution of MD rates in the two groups as estimated with linear mixed
254 models is illustrated in Figure 6. Median (IQR) MD rates in the placebo and
255 treatment cohort were -0.23 (-0.73 to 0.11) dB/year and 0.13 (-0.30 to 0.37) dB/year,
256 respectively ($p<0.001$).

257 In the univariable analysis (Table S2), higher values of all non-fluctuation IOP
258 parameters, including pretreatment baseline IOP (estimate [standard error (SE)]: -
259 0.06 [0.02] dB/year for 1 mmHg increase, $p<0.001$), mean IOP (estimate [SE]: -0.08
260 [0.02] dB/year for 1 mmHg increase, $p<0.001$), peak IOP (estimate [SE]: -0.07 [0.01]
261 dB/year for 1 mmHg increase, $p<0.001$), peak phasing IOP (estimate [SE]: -0.05
262 [0.02] dB/year for 1 mmHg increase, $p<0.001$), and supine IOP (estimate [SE]: -0.06
263 [0.01] dB/year for 1 mmHg increase, $p<0.001$), were significantly associated with
264 faster MD rates in the placebo group. With regards to the IOP fluctuations
265 parameters, higher long-term IOP fluctuation (estimate [SE]: -0.27 [0.07] dB/year for
266 1 mmHg increase, $p<0.001$) and OPA (estimate [SE]: -0.32 [0.09] dB/year for 1
267 mmHg increase, $p<0.001$) were associated with faster MD rates of change, while
268 diurnal IOP fluctuation was not ($p=0.23$). None of the fluctuation parameters was
269 associated with the MD rate after normalizing for the mean IOP ($p=0.11$ or above). In
270 the treatment arm, none of the variables was significantly associated with the MD
271 rate, except for long-term IOP fluctuation (estimate [SE]: -0.12 [0.06] dB/year for 1
272 mmHg increase, $p=0.047$).

273 Results of the multivariable model for factors associated with MD rate of
274 progression are illustrated in Figure 7 and detailed in Table S3. In the placebo arm,
275 PC1, which combined information from all the non-fluctuation IOP parameters, was
276 the only factor associated with the MD rate (estimate [SE]: -0.19 [0.08] dB/year for 1

unit increase, $p < 0.001$), while the various normalized IOP fluctuation metrics were not. Thinner CCT had an association of borderline statistical significance with faster VF progression rates (estimate [SE]: 0.05 [0.02] dB/year for 10 μm thicker, $p = 0.06$). None of the variables was significantly associated with the MD rate of progression in the treatment arm. Older age was associated with faster MD rates (estimate [SE]: -0.12 [0.06] dB/year for a 10-year increase) in the treatment arm, but this only approached nominal statistical significance ($p = 0.06$). Similar results were obtained when analyzing unnormalized IOP fluctuation metrics (Table S4).

Pointwise Rates

Figure 6 illustrates the distribution of pointwise progression rates in the two groups. Pointwise rates were significantly faster in the placebo group than in the treatment group (median [IQR]: -0.42 [-0.59 to -0.26] dB/year vs. 0.03 [-0.14 to 0.19] dB/year, $p < 0.001$). Results of the univariable analysis for factors associated with the pointwise rates of change are illustrated in Table S5. In the placebo group, all the non-fluctuation IOP parameters were significantly associated with the pointwise rates ($p = 0.003$ or below). Higher unnormalized long-term IOP fluctuation (estimate [SE]: -0.34 [0.13] dB/year for 1 mmHg increase, $p = 0.008$) and OPA (estimate [SE]: -0.65 [0.15] dB/year for 1 mmHg increase, $p < 0.001$) were associated with faster pointwise rates of progression. After normalizing IOP fluctuations for mean IOP, only OPA was associated with the rate of progression (estimate [SE]: -1.36 [0.48] dB/year for 1 unit increase, $p = 0.005$). In the treatment arm, none of the IOP variables was associated with the pointwise rates of progression. In the multiple variable model (Figure 8 and Table S6), normalized mean OPA was associated with the pointwise rates of progression in the placebo arm (estimate [SE]: -1.23 [0.46] dB/year for 1 unit

increase, $p=0.009$), but not in the treatment arm. None of the other fluctuation metrics was associated with the rate of progression in either group. The combined IOP metric, PC1, was associated with the pointwise rate of change in the placebo group ($p<0.001$), but not in the treatment group ($p=0.42$). Similarly, none of the unnormalized IOP fluctuation metrics was associated with the pointwise rate of change metrics (Table S7), except for mean OPA in the placebo group (estimate [SE]: -0.47 [0.17] dB/year for 1 mmHg increase, $p=0.008$).

For the five fastest progressing locations, median (IQR) pointwise rates of the five in the placebo and treatment cohort were -1.00 (-1.49 to -0.80) dB/year and -0.52 (-0.93 to -0.34) dB/year, respectively ($p<0.001$). Results of the univariable analysis for factors associated with the rates of the fastest five locations are illustrated in Table S8. In the placebo group, all the non-fluctuation IOP parameters were significantly associated with the pointwise rates ($p=0.003$ or below). Higher unnormalized (estimate [SE]: -1.67 [0.34] dB/year for 1 mmHg increase, $p<0.001$) and normalized OPA (estimate [SE]: -3.95 [1.10] dB/year for 1 unit increase, $p<0.001$) were associated with faster rates of progression. In the treatment arm, higher unnormalized long-term IOP fluctuation was associated with faster rates of progression (estimate [SE]: -0.46 [0.17] dB/year for 1 mmHg increase, $p=0.006$), but the association was no longer significant after normalizing IOP fluctuation (estimate [SE]: -0.81 [0.44] dB/year for 1 unit increase, $p=0.06$). In the multiple variable model (Figure 9 and Table S9), CCT (estimate [SE]: 0.26 [0.10] dB/year for 10 μm thicker, $p=0.01$), normalized OPA (estimate [SE]: -3.50 [1.04] dB/year for 1 unit increase, $p=0.001$), and PC1 (estimate [SE]: -0.58 [0.16] dB/year for 1 PC1 unit increase, $p<0.001$) were associated with the rates of progression of the fastest five test locations in the placebo group; while normalized diurnal and long-term IOP

327 fluctuations were not. In the treatment group, PC1 (estimate [SE]: -0.27 [0.12]
328 dB/year for 1 PC1 unit increase, $p=0.028$) was the only factor associated with
329 progression rates. Results of the nonnormalized models are shown in Table S10.
330 All analyses were repeated with mean IOP, peak IOP and normalized LTF fluctuation
331 calculated from corneal compensated IOP as measured with the Ocular Response
332 Analyzer (Reichert, Inc, Buffalo, NY) and lead to similar results (Figures S10-S14).

DISCUSSION

In this study, we evaluated whether IOP fluctuation was associated with the rate of glaucomatous visual field progression. We provided a comprehensive evaluation of clinically relevant definitions of IOP fluctuation over the course of seconds (OPA), office hours (diurnal fluctuation), and multiple visits over the entire follow-up (long-term fluctuation). We found that higher OPA was associated with faster rates of progression, while diurnal or long-term IOP fluctuations were not associated with the rate of progression. Elevated IOP metrics (e.g., mean IOP, peak IOP) were consistently associated with the rate of VF progression.

Establishing the relationship between IOP fluctuation and the rates of visual field progression is not an easy task for many reasons. First, IOP fluctuation may vary as a function of the time frame over which it is calculated, and there is no consensus on which type of fluctuation is most informative. Our study provided a comprehensive approach, analyzing three measures of fluctuations. Second, the definition of IOP fluctuation is not uniform across studies, with IOP range and SD IOP usually used as measures for IOP fluctuation. It has been suggested that SD IOP could be a more robust metric than range IOP as the latter may be heavily influenced by outliers and does not account for the number of IOP measurements.⁸ In this study, we used SD IOP to calculate diurnal and long-term IOP fluctuation; on the other hand, OPA, a measure of very short-term fluctuation, was an average range of several cardiac cycles. We further mitigated the effect of potential outliers on OPA by obtaining two consecutive OPA measurements at each time point, averaging them to have a single value, and then averaging the resulting values throughout all available follow-up visits. Third, isolating the impact of fluctuation from the level of IOP may be challenging because of the intimate relationship between

these two variables. IOP fluctuation is known to be positively correlated with mean IOP. In a retrospective study performed on non-human primates of experimental glaucoma, Gardiner and colleagues¹⁰ used the coefficient of variation (SD IOP divided by mean IOP) to remove the relationship between these two variables. In our cohort, the coefficient of variation reversed the association with mean IOP values, leading to a negative relationship between IOP fluctuation and mean IOP. The explanation for this is likely that there are two components of variability (measurement error and true IOP fluctuation), one of which (true fluctuation) is related to mean IOP and the other (measurement error) is not.¹⁴ Dividing the measurement error by the mean IOP induces the negative association. The method of normalization used in our study likely respects both the increased fluctuations at higher mean IOP and constant measurement errors. Fourth, IOP-related metrics tend to be highly correlated because they are related to the same original quantity. Modeling highly correlated variables may lead to a statistical issue called multicollinearity. In the presence of multicollinearity, regression models may become inefficient with loss of statistical power, greater computation inaccuracy, unstable estimates, and high variance.¹⁵ Various methods have been proposed to deal with multicollinearity. One or more highly collinear covariates may be omitted from the regression model, which may cause information loss. Ridge regression, a form of penalized linear regression, is another popular method to handle multicollinearity; however, it produces biased estimates and is better suited for predictive rather than explanatory models.¹⁶ In our study, we addressed the issue of multicollinearity with PCA, which creates a new set of orthogonal linear combinations of the original variables (PCs), by definition perfectly uncorrelated to each other.¹⁷ In this study, we used PCA to obtain a maximally informative combined metric of IOP control. Fifth,

clinicians are more likely to escalate treatment in progressing patients, inducing IOP fluctuation. This may be easily overlooked in retrospective cohort studies and even in prospective studies if countermeasures are not adopted. The findings of previous studies have been greatly questioned because of the possible bias caused by medical and surgical treatment escalation. Our study is not vulnerable to the potential confounding effect of treatment escalation as patients in the UKGTS took either latanoprost or placebo for their entire study period. In addition, our study is in the unique position to elucidate the role of IOP fluctuation on glaucomatous progression in untreated patients.

The relationship between IOP fluctuation and glaucomatous progression remains highly controversial, with contrasting results reported in the literature. Comparisons of results from different studies, including ours, should be done with caution because of heterogeneity in study populations, designs, definitions of fluctuation and progression, and statistical analysis. Most of the previous studies focused on long-term (intervisit) IOP fluctuation, which is the most accessible fluctuation metric to obtain as it can be estimated from single IOP measurements from multiple visits. Our study did not find any relationship between long-term IOP fluctuation and VF progression rates. Bengtsson et al.⁵ conducted a post-hoc analysis from the Early Manifest Glaucoma Trial (EMGT); they found that mean IOP was a strong predictor of glaucoma progression, while IOP fluctuation was not. EMGT and UKGTS share many similarities, including the mild disease stage, type of treatment (i.e., nonsurgical intervention), and mean IOP values. An observational study by Medeiros et al.¹⁸ investigated whether IOP fluctuations were associated with the risk of conversion from ocular hypertensive to glaucoma and found that mean IOP, but not long-term IOP fluctuation, was associated with glaucoma

development. Other studies found contrasting results, showing a positive association between long-term IOP fluctuation and VF progression. In a post-hoc analysis of the Advanced Glaucoma Intervention Study (AGIS), Nouri-Mahdavi and colleagues⁹ found that long-term IOP fluctuation was an independent risk factor for glaucoma progression, while mean IOP was not. The results of this study were criticized because the authors analyzed the entire available follow-up, including time points after treatment escalation. Further intervention, either in the form of trabeculectomy or laser trabeculoplasty as per AGIS protocol, might have been itself a cause of clinician-induced increased fluctuation in patients at high risk of progression. In a subsequent post-hoc analysis of the AGIS, Caprioli and Coleman⁸ investigated the relationship between long-term IOP fluctuation and VF progression, excluding those patients having multiple interventions; they found that long-term IOP fluctuations was significantly associated with VF progression in patients with low mean IOP, but not in those with high IOP. A post-hoc analysis from the Collaborative Initial Glaucoma Treatment Study (CIGTS)⁶ examined the role of various IOP parameters on VF progression and found that long-term IOP fluctuation and peak IOP were associated with VF progression, while mean IOP was not.

The literature on the role of diurnal (or diurnal-nocturnal) IOP fluctuation is scarce, of lower quality, and with conflicting reports. In the Malmö Ocular Hypertension study,¹⁹ diurnal IOP fluctuation was not an independent risk factors for the development of glaucoma; conversely, mean IOP was associated with the incidence of glaucomatous visual field loss in patients with OHT. Our study did not find an association between diurnal IOP fluctuation and the rate of glaucomatous progression in any of the models, corroborating the findings of the Malmö Ocular Hypertension study. In a secondary analysis from a Swedish clinical trial

randomizing patients to either pilocarpine or argon laser trabeculoplasty, Bergea et al.²⁰ investigated the relationship between visual field progression and different IOP variables, and they found that both mean IOP and diurnal IOP fluctuation were associated with visual field progression. That study, however, had several limitations, including the small sample size (76 eyes), high proportion of pseudoexfoliation glaucoma (72%), and the use of range IOP as a measure of fluctuation, which is vulnerable to outlier and highly related to peak IOP. A retrospective study by Matlach and colleagues²¹ assessed the impact of long-term and diurnal-nocturnal IOP fluctuation on glaucoma progression in a cohort of 120 glaucoma patients randomly selected from a tertiary referral center; they found that diurnal-nocturnal IOP fluctuation was associated with glaucoma progression, while long-term IOP fluctuation and mean IOP were not. A retrospective study by Kim et al.²² found similar results in a cohort of NTG patients, with higher diurnal IOP fluctuations and disc hemorrhages being associated with higher hazard of visual field progression. Both these studies are limited by their retrospective nature, making them vulnerable to potential confounders and selection bias. Also, these studies did not employ any statistical method to mitigate multicollinearity.

Besides including these two established measures of IOP fluctuation, we also investigated the role of very short-term fluctuation, as measured by the mean ocular pulse amplitude (OPA) over follow-up. OPA is calculated as the difference between systolic and diastolic IOP, as measured by the Pascal dynamic contour tonometer, and informs on how IOP varies across the cardiac cycle, secondary to the pulsatile influx/efflux of blood volume into the eye (mainly to choroid). Ocular pulse may be determined by various ocular and systemic factors, including ocular tissue rigidity,²³⁻²⁵ axial length,²⁶ IOP,^{23, 27} blood pressure pulse amplitude,^{28, 29} left ventricular

ejection time,³⁰ heart rate,^{31, 32} and conditions influencing ocular perfusion (e.g., carotid artery stenosis, tight encircling band).^{33, 34} To the best of our knowledge, there are currently no clinical studies investigating the role of OPA (or any metric for very short IOP fluctuation) on glaucoma progression. We found that higher OPA was significantly associated with faster pointwise rates of progression in the placebo group. Reasons for this finding are speculative. This association may result from an effect of the OPA itself or be related to one or more of its determinants. Animal studies have shown that acute IOP elevation may induce structural optic nerve head deformations and functional electrophysiological changes. Hence, multiple transient IOP spikes may cause faster glaucoma progression in vulnerable eyes. This explanation seems unlikely as these studies investigated large IOP changes, much larger than those measured with OPA. Higher OPA is associated with increased scleral rigidity and stiffer ocular tissues, which may be less compliant to IOP changes, causing larger stress within the lamina cribrosa secondary to IOP elevation.^{35, 36} In a simulation study based on finite element analysis reconstructing a healthy eye model, Jin et al.³⁶ found that stiffer sclera was associated with higher OPA, larger ONH deformation, and increased shearing forces to neural axons of the neuroretinal rim. OPA has been proposed as a surrogate measure for hemodynamics, being influenced by the arterial pulse pressure, heart rate, and left-ventricular ejection time. Low diastolic blood pressure, vascular dysregulation and optic nerve hypoperfusion have been associated with glaucoma progression, especially in some phenotypes of open-angle glaucoma. However, one would expect an opposite association to that found in this study, as lower OPA has been associated with lower ocular blood supply. On the other hand, larger arterial pulse pressure is associated with systemic hypertension, which may lead to vascular

damage. So, high OPA might be a surrogate for hypertensive vascular damage, and previous studies^{37, 38} have shown that high blood pressure may be a risk factors for primary open-angle glaucoma.

Our study confirms the importance of elevated IOP on glaucoma progression. PC1, which combined information from various IOP parameters (i.e., mean IOP, peak IOP, baseline IOP, peak phasing IOP, and supine IOP), was consistently associated with the rate of visual field progression in the placebo group. On the other hand, such a relationship was significant in the treatment group only for the rates of the fastest five visual field locations, but not for global rates of change. The progression rate of the treatment arm was extremely slow during the trial duration, and the signal from a few progressing locations may be obscured by the overall stability of most test locations. Comparative studies^{39, 40} have shown that pointwise methods (especially those considering only locations with significant deterioration) have higher sensitivity and require less time to detect progression than those based on global indices or all test locations. Our study does not provide any information on which IOP metric is the most important for disease progression; this is arduous to tackle because of the intimate relationship among these variables. De Moraes and colleagues² evaluated the effect of mean IOP, peak IOP, and SD IOP in a large retrospective cohort of glaucoma patients under clinical care; they found that all these variables were associated with disease progression in the univariable analysis, but only peak IOP was significantly associated with VF progression in the multivariable model. However, mean IOP and peak IOP are highly correlated, and a multivariable model containing both variables would likely suffer from multicollinearity. Treatment modifications highly influence mean IOP and SD IOP in

real-world settings; although the occurrence of glaucoma surgery during follow-up was taken into consideration, medical treatment escalation was not.

We also investigated the impact of non-IOP and other ocular factors on glaucomatous progression rates, including age, CCT, and corneal hysteresis. The evidence for role of CCT as a risk factor for glaucoma progression is often misunderstood. A thinner cornea causes artifacts in applanation tonometry, with underestimation of the true IOP.⁴¹ Alternatively, corneal thickness may serve as a biomarker of the biomechanical properties of the lamina cribrosa and peripapillary sclera, providing insights into the vulnerability of the optic nerve to increased IOP.⁴² An experimental study by Wells and colleagues⁴³ investigated whether CCT was associated with optic disc compliance after inducing acute IOP rise and found no significant association, indicating that CCT may not reflect ocular biomechanics. In our cohort, thinner CCT was associated with faster progression rates in some multivariable models (which included IOP metrics), while it did not show significance in any of the univariable models. This suggests that CCT alone is not directly associated with glaucoma progression: rather, it becomes statistically significant when measured IOP is included in the model due to the effect of CCT on measured IOP. Other studies, including the Early Manifest Glaucoma Treatment (EMGT)⁴⁴ and the Los Angeles Latino Eye Study (LALES),⁴⁵ found similar finding, associating thin CCT with conversion to glaucoma and incident glaucoma in multivariable models, but not in univariable models. Khawaja and Jansonius⁴⁶ performed a simulation study that mimicked datasets similar to the LALES and Ocular Hypertensive Treatment Study so that IOP, but not CCT, was not associated with glaucoma risk. Consistent with our findings and those from other studies, they found that CCT was not associated with the risk of glaucoma in the univariable model, but a spurious

association between CCT and glaucoma appeared when measured IOP was added to the model.

Although previous studies⁴⁷⁻⁴⁹ have shown a relationship between corneal hysteresis and visual field progression rates, we were not able to confirm such association in our cohort. In any given eye, corneal hysteresis is inversely related to IOP. Therefore, low corneal hysteresis may reflect high IOP, which is an established risk factors for faster glaucoma progression. Also, corneal hysteresis is directly related to corneal stiffness and thickness. Hence, IOP might have underestimated in patients with low corneal hysteresis, with consequent undertreatment leading to faster progression.

Many studies have reported an association between older age and faster progression rates.^{1, 44, 50, 51} In our study, older age was associated with faster MD (but not pointwise) progression rates in the latanoprost group but not in the placebo group. Ageing causes the lamina cribrosa to become stiffer and less compliant, potentially reducing its ability and that of peripapillary sclera to comply with IOP changes. Girard and colleagues³⁵ investigated the age-related biomechanical differences in monkey posterior sclera and found that older animals had higher tensile stress secondary to IOP elevation than younger ones. As tensile stress increased non-linearly with IOP rise, the impact of ageing should theoretically be more pronounced in patients with higher mean IOP; however, we found that older age was associated with worse progression rates in the treatment arm, which had lower mean IOP than the placebo arm. This finding is in agreement with a large retrospective cohort study by De Moraes and colleagues², reporting that older age was independently associated with glaucomatous VF progression only in patients with lower mean IOP. Similar findings were found in the JAMDIG study, a large

retrospective study conducted in Japanese patients with fairly low mean IOP values.⁵⁰ An explanation to these findings may be that the impact of non-IOP factors, including age, becomes more important only after substantially lowering the IOP.

This study has limitations. This was a planned secondary analysis based on the UKGTS dataset and the number of subjects and the duration of follow-up may not provide enough statistical power to identify a meaningful relationship between IOP fluctuation and visual field progression, especially in the treatment arm, where progression rates were extremely slow over the study period. The study cohort included treatment-naïve primary open-glaucoma patients, mainly of European descent and with early glaucomatous damage. Some authors¹¹ have hypothesized that the effect of IOP fluctuation on the rates of visual progression might vary as a function of disease stage, mean IOP, glaucoma subtype, ethnicity, and treatment modality (medical vs surgical intervention); hence, the results of this study may be not entirely generalizable to other populations. Nevertheless, the results of this study are in agreement with those from the EMGT analysis.⁵ The diurnal IOP fluctuation calculation was based on five measurements obtained during the morning and afternoon, and this study provides only IOP snapshots across the day and no information on IOP fluctuation outside office hours. Although we used clinically relevant definitions of IOP fluctuation, these measurements may not adequately characterize short-term IOP variability. Diurnal phasing has been shown to be poorly reproducible, indicating that single-day IOP measurements may not be sufficient to accurately assess short-term fluctuations.⁵²⁻⁵⁵ Our findings are consistent with existing literature in this field. A comparison between the two available diurnal IOP curves revealed that the 95% limits of agreement were around 4 mmHg, aligning closely with the most pronounced fluctuation extremes observed in this dataset

(Figure S15). Differences between diurnal IOP fluctuation calculated in the first and last post-randomization visits were random and approximate a normal distribution (Figure S16). Several studies^{56, 57} have documented a nocturnal peak in IOP, primarily attributed to an increase in episcleral venous pressure when the body is in a horizontal position. Although our study did not include night-time IOP measurements, we did record IOP in a supine position, which is recognized as a reasonable proxy for estimating nocturnal peak levels.⁵⁸ While devices for home IOP monitoring^{59, 60} or continuous IOP tracking^{61, 62} have been introduced, they were not collected in the UKGTS study and are generally reserved for research rather than routine clinical use. Although the methodology employed in this study may not capture the entire spectrum or precise patterns of IOP fluctuations, we adopted a clinically relevant approach to defining diurnal IOP fluctuation.

In conclusion, this study finds no evidence to support that either diurnal or long-term IOP fluctuation, defined in a clinically relevant manner, are independent factors for glaucoma progression. Other aspects of IOP, such as mean IOP and peak IOP, may be more informative. Higher OPA may be an independent factor for faster glaucoma progression.

599 **ACKNOWLEDGMENTS**

600 The trial sponsor was Moorfields Eye Hospital NHS Foundation Trust. The
601 principal funding was through an unrestricted investigator-initiated research grant
602 from Pfizer, with supplementary funding from the UK's NIHR Biomedical Research
603 Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
604 Ophthalmology, London, UK. Equipment loans were made by Heidelberg
605 Engineering, Carl Zeiss Meditec and Optovue (Optovue, Fremont, CA, USA). DFG-
606 H's chair at UCL is supported by funding from the nonprofit association Glaucoma
607 UK.

608 **Declaration of Generative AI and AI-assisted technologies in the writing**
609 **process**

610

611 During the preparation of this work the authors used chatGPT3.5 in order to improve
612 readability and language of the manuscript. After using this tool/service, the authors
613 reviewed and edited the content as needed and take full responsibility for the content
614 of the publication.

REFERENCES

1. Kim JH, Rabiolo A, Morales E, et al. Risk Factors for Fast Visual Field Progression in Glaucoma. *Am J Ophthalmol* 2019;207:268-78.
2. De Moraes CG, Juthani VJ, Liebmann JM, et al. Risk factors for visual field progression in treated glaucoma. *Arch Ophthalmol* 2011;129(5):562-8.
3. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet* 2015;385(9975):1295-304.
4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol* 2002;120(6):714-20; discussion 829-30.
5. Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(2):205-9.
6. Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2011;118(9):1766-73.
7. Lee PP, Walt JW, Rosenblatt LC, et al. Association between intraocular pressure variation and glaucoma progression: data from a United States chart review. *Am J Ophthalmol* 2007;144(6):901-7.
8. Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. *Ophthalmology* 2008;115(7):1123-9 e3.

- 638 9. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for
 639 glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.
 640 Ophthalmology 2004;111(9):1627-35.
- 641 10. Gardiner SK, Fortune B, Wang L, et al. Intraocular pressure magnitude and
 642 variability as predictors of rates of structural change in non-human primate
 643 experimental glaucoma. Exp Eye Res 2012;103:1-8.
- 644 11. Kim JH, Caprioli J. Intraocular Pressure Fluctuation: Is It Important? J
 645 Ophthalmic Vis Res 2018;13(2):170-4.
- 646 12. Lascaratos G, Garway-Heath DF, Burton R, et al. The United Kingdom
 647 Glaucoma Treatment Study: a multicenter, randomized, double-masked, placebo-
 648 controlled trial: baseline characteristics. Ophthalmology 2013;120(12):2540-5.
- 649 13. Garway-Heath DF, Lascaratos G, Bunce C, et al. The United Kingdom
 650 Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical
 651 trial: design and methodology. Ophthalmology 2013;120(1):68-76.
- 652 14. Kotecha A, White E, Schlottmann PG, Garway-Heath DF. Intraocular pressure
 653 measurement precision with the Goldmann applanation, dynamic contour, and ocular
 654 response analyzer tonometers. Ophthalmology 2010;117(4):730-7.
- 655 15. Gunst RF. Regresion analysis with multicollinear predictor variables:
 656 definition, derection, and effects. Communications in Statistics - Theory and Methods
 657 1983;12(19):2217-60.
- 658 16. Mahajan V, Jain AK, Bergier M. Parameter Estimation in Marketing Models in
 659 the Presence of Multicollinearity: An Application of Ridge Regression. Journal of
 660 Marketing Research 1977;14(4):586-91.
- 661 17. Morzuch BJ, Ruark GA. Principal Components Regression to Mitigate the
 662 Effects of Multicollinearity. Forest Science 1991;37(1):191-9.

- 663 18. Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure
664 fluctuations and risk of conversion from ocular hypertension to glaucoma.
665 *Ophthalmology* 2008;115(6):934-40.
- 666 19. Bengtsson B, Heijl A. Diurnal IOP fluctuation: not an independent risk factor
667 for glaucomatous visual field loss in high-risk ocular hypertension. *Graefes Arch Clin*
668 *Exp Ophthalmol* 2005;243(6):513-8.
- 669 20. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on
670 visual fields in open-angle glaucoma. *Ophthalmology* 1999;106(5):997-1004;
671 discussion -5.
- 672 21. Matlach J, Bender S, Konig J, et al. Investigation of intraocular pressure
673 fluctuation as a risk factor of glaucoma progression. *Clin Ophthalmol* 2019;13:9-16.
- 674 22. Kim SH, Lee EJ, Han JC, et al. The Effect of Diurnal Fluctuation in Intraocular
675 Pressure on the Evaluation of Risk Factors of Progression in Normal Tension
676 Glaucoma. *PLoS One* 2016;11(10):e0164876.
- 677 23. Dastiridou AI, Ginis HS, De Brouwere D, et al. Ocular rigidity, ocular pulse
678 amplitude, and pulsatile ocular blood flow: the effect of intraocular pressure. *Invest*
679 *Ophthalmol Vis Sci* 2009;50(12):5718-22.
- 680 24. Ma Y, Moroi SE, Roberts CJ. Non-invasive Clinical Measurement of Ocular
681 Rigidity and Comparison to Biomechanical and Morphological Parameters in
682 Glaucomatous and Healthy Subjects. *Front Med (Lausanne)* 2021;8:701997.
- 683 25. Markert JE, Turner DC, Jasien JV, et al. Ocular Pulse Amplitude Correlates
684 With Ocular Rigidity at Native IOP Despite the Variability in Intraocular Pulse Volume
685 With Each Heartbeat. *Transl Vis Sci Technol* 2022;11(9):6.

- 686 26. Dastiridou AI, Ginis H, Tsilimbaris M, et al. Ocular rigidity, ocular pulse
687 amplitude, and pulsatile ocular blood flow: the effect of axial length. *Invest*
688 *Ophthalmol Vis Sci* 2013;54(3):2087-92.
- 689 27. Choi J, Lee J, Park SB, et al. Factors affecting ocular pulse amplitude in eyes
690 with open angle glaucoma and glaucoma-suspect eyes. *Acta Ophthalmol*
691 2012;90(6):552-8.
- 692 28. Abegao Pinto L, Vandewalle E, Willekens K, et al. Ocular pulse amplitude and
693 Doppler waveform analysis in glaucoma patients. *Acta Ophthalmol* 2014;92(4):e280-
694 5.
- 695 29. Kim YJ, Lee KS, Lee JR, et al. Ocular pulse amplitude as a dynamic
696 parameter and its relationship with 24-h intraocular pressure and blood pressure in
697 glaucoma. *Exp Eye Res* 2013;115:65-72.
- 698 30. Grieshaber MC, Katamay R, Gugleta K, et al. Relationship between ocular
699 pulse amplitude and systemic blood pressure measurements. *Acta Ophthalmol*
700 2009;87(3):329-34.
- 701 31. Trew DR, James CB, Thomas SH, et al. Factors influencing the ocular pulse--
702 the heart rate. *Graefes Arch Clin Exp Ophthalmol* 1991;229(6):553-6.
- 703 32. Gekkieva M, Orgul S, Gherghel D, et al. The influence of sex difference in
704 measurements with the Langham Ocular Blood Flow System. *Jpn J Ophthalmol*
705 2001;45(5):528-32.
- 706 33. Knecht PB, Menghini M, Bachmann LM, et al. The ocular pulse amplitude as
707 a noninvasive parameter for carotid artery stenosis screening: a test accuracy study.
708 *Ophthalmology* 2012;119(6):1244-9.
- 709 34. Lincoff H, Stopa M, Kreissig I, et al. Cutting the encircling band. *Retina*
710 2006;26(6):650-4.

- 711 35. Girard MJ, Suh JK, Bottlang M, et al. Scleral biomechanics in the aging
712 monkey eye. *Invest Ophthalmol Vis Sci* 2009;50(11):5226-37.
- 713 36. Jin Y, Wang X, Zhang L, et al. Modeling the Origin of the Ocular Pulse and Its
714 Impact on the Optic Nerve Head. *Invest Ophthalmol Vis Sci* 2018;59(10):3997-4010.
- 715 37. Bae HW, Lee N, Lee HS, et al. Systemic hypertension as a risk factor for
716 open-angle glaucoma: a meta-analysis of population-based studies. *PLoS One*
717 2014;9(9):e108226.
- 718 38. Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and
719 primary open-angle glaucoma: a meta-analysis. *Am J Ophthalmol* 2014;158(3):615-
720 27 e9.
- 721 39. Rabiolo A, Morales E, Mohamed L, et al. Comparison of Methods to Detect
722 and Measure Glaucomatous Visual Field Progression. *Transl Vis Sci Technol*
723 2019;8(5):2.
- 724 40. Mayama C, Araie M, Suzuki Y, et al. Statistical evaluation of the diagnostic
725 accuracy of methods used to determine the progression of visual field defects in
726 glaucoma. *Ophthalmology* 2004;111(11):2117-25.
- 727 41. Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on
728 applanation tonometry. *Am J Ophthalmol* 1993;115(5):592-6.
- 729 42. Lesk MR, Hafez AS, Descovich D. Relationship between central corneal
730 thickness and changes of optic nerve head topography and blood flow after
731 intraocular pressure reduction in open-angle glaucoma and ocular hypertension.
732 *Arch Ophthalmol* 2006;124(11):1568-72.
- 733 43. Wells AP, Garway-Heath DF, Poostchi A, et al. Corneal hysteresis but not
734 corneal thickness correlates with optic nerve surface compliance in glaucoma
735 patients. *Invest Ophthalmol Vis Sci* 2008;49(8):3262-8.

- 736 44. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the
737 early manifest glaucoma trial. *Ophthalmology* 2007;114(11):1965-72.
- 738 45. Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the
739 development of open-angle glaucoma in a population: the Los Angeles Latino Eye
740 Study. *Ophthalmology* 2012;119(11):2245-53.
- 741 46. Khawaja AP, Jansonius NM. Potential for Collider Bias in Studies Examining
742 the Association of Central Corneal Thickness With Glaucoma. *Invest Ophthalmol Vis*
743 *Sci* 2022;63(12):3.
- 744 47. Medeiros FA, Meira-Freitas D, Lisboa R, et al. Corneal hysteresis as a risk
745 factor for glaucoma progression: a prospective longitudinal study. *Ophthalmology*
746 2013;120(8):1533-40.
- 747 48. Chan E, Yeh K, Moghimi S, et al. Changes in Corneal Biomechanics and
748 Glaucomatous Visual Field Loss. *J Glaucoma* 2021;30(5):e246-e51.
- 749 49. Kamalipour A, Moghimi S, Eslani M, et al. A Prospective Longitudinal Study to
750 Investigate Corneal Hysteresis as a Risk Factor of Central Visual Field Progression
751 in Glaucoma. *Am J Ophthalmol* 2022;240:159-69.
- 752 50. Fujino Y, Asaoka R, Murata H, et al. Evaluation of Glaucoma Progression in
753 Large-Scale Clinical Data: The Japanese Archive of Multicentral Databases in
754 Glaucoma (JAMDIG). *Invest Ophthalmol Vis Sci* 2016;57(4):2012-20.
- 755 51. Bommakanti N, De Moraes CG, Boland MV, et al. Baseline Age and Mean
756 Deviation Affect the Rate of Glaucomatous Vision Loss. *J Glaucoma* 2020;29(1):31-
757 8.
- 758 52. Aptel F, Lesoin A, Chiquet C, et al. Long-term reproducibility of diurnal
759 intraocular pressure patterns in patients with glaucoma. *Ophthalmology*
760 2014;121(10):1998-2003.

- 761 53. Realini T, Weinreb RN, Wisniewski S. Short-term repeatability of diurnal
762 intraocular pressure patterns in glaucomatous individuals. *Ophthalmology*
763 2011;118(1):47-51.
- 764 54. Realini T, Weinreb RN, Wisniewski SR. Diurnal intraocular pressure patterns
765 are not repeatable in the short term in healthy individuals. *Ophthalmology*
766 2010;117(9):1700-4.
- 767 55. Hatanaka M, Babic M, Susanna R, Jr. Reproducibility of the mean, fluctuation,
768 and IOP peak in the diurnal tension curve. *J Glaucoma* 2013;22(5):390-2.
- 769 56. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular
770 pressure in young adults. *Invest Ophthalmol Vis Sci* 1998;39(13):2707-12.
- 771 57. Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular
772 pressure pattern associated with early glaucomatous changes. *Invest Ophthalmol*
773 *Vis Sci* 2003;44(4):1586-90.
- 774 58. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak
775 nocturnal intraocular pressures in healthy subjects and glaucoma patients. *Am J*
776 *Ophthalmol* 2005;139(2):320-4.
- 777 59. Sakamoto M, Kanamori A, Fujihara M, et al. Assessment of IcareONE
778 rebound tonometer for self-measuring intraocular pressure. *Acta Ophthalmol*
779 2014;92(3):243-8.
- 780 60. Halkiadakis I, Stratos A, Stergiopoulos G, et al. Evaluation of the Icare-ONE
781 rebound tonometer as a self-measuring intraocular pressure device in normal
782 subjects. *Graefes Arch Clin Exp Ophthalmol* 2012;250(8):1207-11.
- 783 61. Mansouri K, Weinreb RN, Liu JH. Efficacy of a contact lens sensor for
784 monitoring 24-h intraocular pressure related patterns. *PLoS One*
785 2015;10(5):e0125530.

786 62. Marando CM, Mansouri K, Kahook MY, Seibold LK. Tolerability and
787 Functionality of a Wireless 24-Hour Ocular Telemetry Sensor in African American
788 Glaucoma Patients. J Glaucoma 2019;28(2):119-24.

789

FIGURE LEGENDS

Figure 5. Boxplots comparing the various IOP metrics in the placebo and treatment groups. IOP: intraocular pressure; MD: mean deviation; OPA: ocular pulse amplitude; SD: standard deviation.

Figure 6. Density plots for the distribution of MD (**left panel**) and pointwise (**right panel**) rates of progression in the placebo and latanoprost groups. MD: mean deviation. PLR: pointwise linear rates.

Figure 7. Forest plots for factors associated with the MD rates of progression in the placebo (**left panel**) and treatment (**right panel**) group. Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. Combined IOP metrics PC1 is a unitless variable, which combines fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; MD: mean deviation; OPA: ocular pulse amplitude; PC1: principal component 1.

Figure 8. Forest plots for factors associated with the pointwise rates of progression in the placebo (**left panel**) and treatment (**right panel**) group. Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. Combined IOP metrics PC1 is a unitless variable, which combines fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component

815 Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular
816 pressure; OPA: ocular pulse amplitude; PC1: principal component 1; PLR: pointwise
817 linear rates.

818

819 **Figure 9.** Forest plots for factors associated with the pointwise rates of progression
820 of the five fastest locations in the placebo **(left panel)** and treatment **(right panel)**
821 group. Dots and bars indicate point estimates and 95% confidence intervals,
822 respectively. Estimates are intended for 1-unit increase, unless specified otherwise.
823 Combined IOP metrics PC1 is an unitless variable, which combines fluctuation
824 unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak
825 phasing IOP) through Principal Component Analysis. CCT: central corneal thickness;
826 CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude;
827 PC1: principal component 1; PLR: pointwise linear rates.

Figure 5

[Click here to access/download;Figure;Figure 5.tiff](#)




Figure 6






Figure 7

[Click here to access/download;Figure;Figure 7.tiff](#)

MD RATE



PLR – ALL LOCATIONS



PLR – 5 FASTEST LOCATIONS





Table 1. Baseline demographic and clinical characteristics of the study population		
Variable	Placebo Cohort	Treatment Cohort
No. Eyes/Patients	213/213	217/217
Age, years, mean ($\pm$ SD)	66.5 ($\pm$ 10.3)	65.1 ($\pm$ 10.4)
Sex, male/female	105/108	119/98
Eye, right / left	92/121	80/137
Ethnicity		
White	193 (90.6%)	197 (90.8%)
Black	11 (5.2%)	7 (3.2%)
Asian	5 (2.3%)	9 (4.2%)
Other	1 (0.5%)	2 (0.9%)
Unknown	3 (1.4%)	2 (0.9%)
Baseline IOP, mmHg, mean ($\pm$ SD)	19.5 (16.0 to 22.8)	19.3 (16.5 to 22.0)
Baseline MD, dB, median (IQR)	-3.4 (-2.0 to -5.6)	-3.4 (-2.1 to -5.4)
CCT, micron, mean ($\pm$ SD)	544 ($\pm$ 34)	539 ($\pm$ 34)
CCT: central corneal thickness, IOP: intraocular pressure; IQR: interquartile range; MD: mean deviation; SD: standard deviation.		

UNNORMALIZED



NORMALIZED




Figure S1. Bivariate plots showing the relationship between mean IOPs and the various unnormalized (**top row**) and normalized (**bottom row**) IOP fluctuation metrics. Blue lines and grey shadow represent regression lines and 95% confidence intervals, respectively. IOP: intraocular pressure; OPA: ocular pulse amplitude; SD: standard deviation.

Figure S2





Figure S2. Hierarchical cluster analysis of covariates based on the absolute value of Spearman's correlation coefficient for original variables (**left panel**) and after combining baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP into a combined IOP metric through PCA (**right panel**). IOP: intraocular pressure; OPA: ocular pulse amplitude; PCA: principal component analysis; PC1: principal component 1.

Figure S3

PCA BIPLLOT



PCA SCREE PLOT





Figure S3. Principal component analysis (PCA) Biplot (**left panel**) and scree plot (**right panel**). IOP: intraocular pressure; PC1: principal component 1; PC2: principal component 2.

Figure S4

Proportion of Missing Data



Patterns of Missing Data




Figure S4. Fraction of missing data for each variable (**left panel**) and hierarchical cluster analysis of missingness combinations (**right panel**). ACD: anterior chamber depth; AXL: axial length; BMI: body mass index; CCT: central corneal thickness; IOP: intraocular pressure; MD: mean deviation; OPA: ocular pulse amplitude; VA: visual acuity.



GAT IOP

ORA IOPcc

LONG-TERM GAT IOP FLUCTUATION

LONG-TERM IOPcc FLUCTUATION

UNNORMALIZED



LONG-TERM GAT IOP FLUCTUATION

LONG-TERM IOPcc FLUCTUATION

NORMALIZED





Figure S10. Bivariate plots showing the relationship between mean IOP and long-term IOP fluctuation as measured with GAT (**left column**) and ORA (**right column**). Blue lines and grey shadow represent regression lines and 95% confidence intervals, respectively. GAT: Goldmann applanation tonometer; IOP: intraocular pressure; IOPcc: corneal-compensated IOP; ORA: ocular response analyzer; SD: standard deviation.

Figure S11




Figure S11. Principal component analysis (PCA) biplot (**left panel**) and scree plot (**right panel**) using IOPcc values to estimate mean and peak IOP. IOP: intraocular pressure; IOPcc: corneal-compensated IOP; PC1: principal component 1; PC2: principal component 2.

MD RATE




Figure S12. Forest plots for factors associated with the MD rates of progression in the placebo (**left panel**) and treatment (**right panel**) group. Mean IOP, peak IOP and normalized LTF fluctuation were calculated from corneal compensated IOP as measured with the Ocular Response Analyzer (Reichert, Inc, Buffalo, NY). Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. CCT: central corneal thickness; IOP: intraocular pressure; IOPcc: corneal-compensated IOP; MD: mean deviation; OPA: ocular pulse amplitude; PC1: principal component 1

PLR – ALL LOCATIONS




Figure S13. Forest plots for factors associated with the pointwise rates of progression in the placebo (**left panel**) and treatment (**right panel**) group. Mean IOP, peak IOP and normalized LTF fluctuation were calculated from corneal compensated IOP as measured with the Ocular Response Analyzer (Reichert, Inc, Buffalo, NY). Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. CCT: central corneal thickness; IOP: intraocular pressure; IOPcc: corneal-compensated IOP; MD: mean deviation; OPA: ocular pulse amplitude; PC1: principal component 1

PLR – 5 FASTEST LOCATIONS




Figure S14. Forest plots for factors associated with the pointwise rates of progression of the fastest five locations in the placebo (**left panel**) and treatment (**right panel**) group. Mean IOP, peak IOP and normalized LTF fluctuation were calculated from corneal compensated IOP as measured with the Ocular Response Analyzer (Reichert, Inc, Buffalo, NY). Dots and bars indicate point estimates and 95% confidence intervals, respectively. Estimates are intended for 1-unit increase, unless specified otherwise. CCT: central corneal thickness; IOP: intraocular pressure; IOPcc: corneal-compensated IOP; MD: mean deviation; OPA: ocular pulse amplitude; PC1: principal component 1

Figure S15

DIURNAL IOP FLUCTUATION




Figure S15. Bland-Altman plots of agreement for diurnal IOP fluctuation calculated from the IOP phasing performed at the first and last post-randomization visits. Black solid line and red dashed lines indicate the no difference lines. and 95% limits of agreements, respectively.

Figure S16

DIURNAL SD IOP DIFFERENCES BETWEEN LAST AND FIRST PHASING




Figure S16. Frequency histogram (**left panel**) and quantile-quantile plot (**right panel**) for the difference in IOP fluctuation values calculated from IOP phasings performed at the last and first post-randomization visits.

Table S2. Univariable analysis for factors associated with the MD rate of progression				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	-0.01 (0.08)	0.89	-0.08 (0.06)	0.18
CCT, per 10 μm	0.02 (0.02)	0.34	-0.02 (0.02)	0.35
CH	0.05 (0.05)	0.34	0.05 (0.04)	0.25
Baseline IOP	-0.06 (0.02)	<0.001	0.00 (0.01)	0.77
Mean IOP	-0.08 (0.02)	<0.001	-0.03 (0.02)	0.18
Peak IOP	-0.07 (0.01)	<0.001	-0.02 (0.01)	0.10
Peak Phasing IOP	-0.05 (0.02)	<0.001	-0.02 (0.02)	0.14
Supine IOP	-0.06 (0.01)	<0.001	-0.01 (0.02)	0.49
OPA	-0.32 (0.09)	<0.001	-0.04 (0.08)	0.62
Long-term Fluctuation	-0.27 (0.07)	<0.001	-0.12 (0.06)	0.047
Diurnal Fluctuation	-0.11 (0.09)	0.23	-0.09 (0.09)	0.35
Normalized OPA	-0.42 (0.26)	0.11	0.02 (0.18)	0.90
Normalized long-term Fluctuation	-0.28 (0.20)	0.17	-0.16 (0.15)	0.30
Normalized diurnal Fluctuation	0.05 (0.15)	0.77	-0.01 (0.13)	0.91
Estimates are intended for 1-unit increase unless specified otherwise. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude; SE: standard error.				

Table S3. Multivariable analysis for factors associated with the MD rate of progression				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	0.01 (0.08)	0.95	-0.12 (0.06)	0.06
CCT, per 10 µm	0.05 (0.02)	0.06	-0.02 (0.02)	0.23
CH	-0.02 (0.05)	0.73	0.05 (0.04)	0.25
Normalized OPA	-0.30 (0.26)	0.24	-0.06 (0.18)	0.72
Normalized long-term Fluctuation	-0.27 (0.21)	0.20	-0.12 (0.17)	0.49
Normalized diurnal Fluctuation	0.16 (0.15)	0.31	-0.02 (0.14)	0.88
Combined IOP metrics – PC1	-0.19 (0.04)	<0.001	-0.05 (0.04)	0.23
Estimates are intended for 1-unit increase. Combined IOP metrics PC1 is a unitless variable, combining fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; PC1: principal component 1; SE: standard error.				

Table S4. Multivariable analysis for factors associated with the MD rate of progression				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	0.02 (0.08)	0.85	-0.13 (0.06)	0.037
CCT, per 10 µm	0.05 (0.02)	0.056	-0.03 (0.02)	0.19
CH	-0.02 (0.05)	0.73	0.04 (0.04)	0.32
OPA	-0.15 (0.10)	0.11	-0.05 (0.08)	0.54
Long-term Fluctuation	-0.12 (0.09)	0.17	-0.12 (0.08)	0.11
Diurnal Fluctuation	0.09 (0.10)	0.35	-0.06 (0.11)	0.61
Combined IOP metrics – PC1	-0.14 (0.05)	0.005	0.00 (0.05)	0.95
Estimates are intended for 1-unit increase. Combined IOP metrics PC1 is an unitless variable, combining fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude; PC1: principal component 1; SE: standard error.				

Table S5. Univariable analysis for factors associated with the pointwise rate of progression				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	-0.04 (0.14)	0.78	-0.04 (0.09)	0.67
CCT, per 10 μm	0.03 (0.04)	0.50	0.01 (0.03)	0.84
CH	0.07 (0.09)	0.49	0.10 (0.06)	0.12
Baseline IOP	-0.09 (0.03)	0.003	0.00 (0.02)	0.87
Mean IOP	-0.13 (0.03)	<0.001	-0.03 (0.03)	0.36
Peak IOP	-0.11 (0.03)	<0.001	-0.02 (0.02)	0.30
Peak IOP Phasing	-0.09 (0.03)	<0.001	-0.02 (0.03)	0.32
Supine IOP	-0.10 (0.03)	<0.001	0.00 (0.02)	0.86
OPA	-0.65 (0.15)	<0.001	0.11 (0.11)	0.32
Long-term Fluctuation	-0.34 (0.13)	0.008	-0.12 (0.08)	0.16
Diurnal Fluctuation	-0.22 (0.15)	0.14	-0.08 (0.13)	0.53
Normalized OPA	-1.36 (0.48)	0.005	0.48 (0.26)	0.07
Normalized Long-term Fluctuation	-0.36 (0.35)	0.32	-0.12 (0.22)	0.58
Normalized Diurnal Fluctuation	-0.02 (0.29)	0.93	-0.01 (0.20)	0.97
Estimates are intended for 1-unit increase, unless specified otherwise. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: Ocular Pulse Amplitude; SE: standard error.				

Table S6. Multivariable analysis for factors associated with the pointwise rate of progression				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	0.04 (0.14)	0.79	-0.06 (0.09)	0.52
CCT, per 10 µm	0.07 (0.04)	0.11	0.01 (0.03)	0.81
CH	-0.05 (0.10)	0.59	0.11 (0.07)	0.11
Normalized OPA	-1.23 (0.46)	0.009	0.52 (0.27)	0.055
Normalized Long-term Fluctuation	-0.23 (0.35)	0.52	0.06 (0.25)	0.81
Normalized Diurnal Fluctuation	0.13 (0.28)	0.63	-0.06 (0.21)	0.77
Combined IOP metrics – PC1	-0.29 (0.07)	<0.001	-0.05 (0.06)	0.42
Estimates are intended for 1-unit increase unless specified otherwise. Combined IOP metrics PC1 is an unitless variable, combining fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude; PC1: principal component 1; SE: standard error.				

Table S7. Multivariable analysis for factors associated with the pointwise rate of progression				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	0.05 (0.14)	0.74	-0.07 (0.09)	0.44
CCT, per 10 µm	0.07 (0.04)	0.13	0.01 (0.03)	0.84
CH	-0.05 (0.10)	0.60	0.10 (0.07)	0.15
OPA	-0.47 (0.17)	0.008	0.18 (0.12)	0.14
Long-term Fluctuation	-0.09 (0.14)	0.54	-0.06 (0.11)	0.60
Diurnal Fluctuation	0.03 (0.16)	0.87	-0.09 (0.14)	0.55
Combined IOP metrics – PC1	-0.17 (0.09)	0.06	-0.05 (0.08)	0.50
Estimates are intended for 1-unit increase unless specified otherwise. Combined IOP metrics PC1 is an unitless variable, combining fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude; PC1: principal component 1; SE: standard error.				

Table S8. Univariable analysis for factors associated with the rate of fastest five locations				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	-0.42 (0.33)	0.19	-0.16 (0.17)	0.37
CCT, per 10 µm	0.15 (0.10)	0.11	0.01 (0.05)	0.88
CH	0.25 (0.22)	0.26	0.15 (0.12)	0.24
Baseline IOP	-0.21 (0.07)	0.003	-0.07 (0.04)	0.06
Mean IOP	-0.27 (0.07)	<0.001	-0.09 (0.05)	0.09
Peak IOP	-0.19 (0.06)	0.002	-0.07 (0.04)	0.07
Peak IOP Phasing	-0.20 (0.06)	0.002	-0.08 (0.05)	0.12
Supine IOP	-0.21 (0.06)	<0.001	-0.01 (0.05)	0.80
OPA	-1.67 (0.34)	<0.001	-0.24 (0.28)	0.28
Long-term Fluctuation	-0.49 (0.30)	0.11	-0.46 (0.17)	0.006
Diurnal Fluctuation	-0.56 (0.34)	0.10	-0.33 (0.26)	0.20
Normalized OPA	-3.95 (1.10)	<0.001	-0.19 (0.52)	0.71
Normalized Long-term Fluctuation	0.23 (0.83)	0.79	-0.81 (0.44)	0.06
Normalized Diurnal Fluctuation	-0.15 (0.65)	0.82	-0.19 (0.40)	0.63
Estimates are intended for 1-unit increase, unless specified otherwise. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: Ocular Pulse Amplitude; SE: standard error.				

Table S9. Multivariable analysis for factors associated with the rate of fastest five locations				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	-0.13 (0.33)	0.69	-0.19 (0.18)	0.28
CCT, per 10 μm	0.26 (0.10)	0.010	0.01 (0.06)	0.93
CH	-0.09 (0.22)	0.69	0.13 (0.13)	0.31
Normalized OPA	-3.50 (1.04)	0.001	-0.38 (0.51)	0.46
Normalized Long-term Fluctuation	0.48 (0.80)	0.55	-0.71 (0.47)	0.13
Normalized Diurnal Fluctuation	0.20 (0.62)	0.75	-0.28 (0.39)	0.48
Combined IOP metrics – PC1	-0.58 (0.16)	<0.001	-0.27 (0.12)	0.028
Estimates are intended for 1-unit increase unless specified otherwise. Combined IOP metrics PC1 is an unitless variable, combining fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude; PC1: principal component 1; SE: standard error.				

Table S10. Multivariable analysis for factors associated with the rate of fastest five locations				
	PLACEBO		TREATMENT	
Variable	Est (SE)	p-value	Est (SE)	p-value
Baseline Age, decades	-0.14 (0.32)	0.66	-0.24 (0.18)	0.18
CCT, per 10 µm	0.24 (0.10)	0.016	0.01 (0.06)	0.91
CH	-0.09 (0.22)	0.66	0.11 (0.13)	0.40
OPA	-1.36 (0.39)	<0.001	-0.19 (0.23)	0.40
Long-term Fluctuation	0.12 (0.33)	0.73	-0.47 (0.22)	0.032
Diurnal Fluctuation	-0.06 (0.36)	0.87	-0.33 (0.27)	0.22
Combined IOP metrics – PC1	-0.32 (0.21)	0.13	-0.06 (0.15)	0.71
Estimates are intended for 1-unit increase unless specified otherwise. Combined IOP metrics PC1 is an unitless variable, combining fluctuation unrelated IOP metrics (baseline IOP, peak IOP, mean IOP, supine IOP, peak phasing IOP) through Principal Component Analysis. CCT: central corneal thickness; CH: corneal hysteresis; IOP: intraocular pressure; OPA: ocular pulse amplitude; PC1: principal component 1; SE: standard error.				

ICMJE FORM

Date: 10/4/2023

Your Name: David Crabb

Manuscript Title: Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS)

US-based Author (if yes, you must fill out Open Payment section below): NO

Manuscript Number (if known): [Click or tap here to enter text.](#)

Ophthalmology complies with the position of the International Committee of Medical Journal Editors (ICMJE) on "Conflict of Interest." Conflict of interest for authors is defined as "financial and other conflicts of interest that might bias their work."

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)										
Time frame: Since the initial planning of the work												
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>						Click the tab key to add additional rows.				
	Click the tab key to add additional rows.											
Time frame: past 36 months												
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ None <table border="1"> <tr><td>Santen</td><td>Financial support</td></tr> <tr><td>Allergan</td><td>Financial support</td></tr> <tr><td>AbbVie</td><td>Financial support</td></tr> <tr><td>Apellis Pharmaceuticals</td><td>Financial support</td></tr> <tr><td>CenterVue-Icare</td><td>Financial support</td></tr> </table>	Santen	Financial support	Allergan	Financial support	AbbVie	Financial support	Apellis Pharmaceuticals	Financial support	CenterVue-Icare	Financial support
Santen	Financial support											
Allergan	Financial support											
AbbVie	Financial support											
Apellis Pharmaceuticals	Financial support											
CenterVue-Icare	Financial support											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)										
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>											
4	Consulting fees	☐ None <table border="1"> <tr><td>Allergan</td><td></td></tr> <tr><td>Apellis Pharmaceuticals</td><td></td></tr> <tr><td>CenterVue-Icare</td><td></td></tr> <tr><td>Thea</td><td></td></tr> <tr><td>Roche</td><td></td></tr> </table>		Allergan		Apellis Pharmaceuticals		CenterVue-Icare		Thea		Roche	
Allergan													
Apellis Pharmaceuticals													
CenterVue-Icare													
Thea													
Roche													
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>											
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>											
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>											
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>											
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>											
10	Leadership or fiduciary role in	☒ None											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
	other board, society, committee or advocacy group, paid or unpaid	<table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
11	Stock or stock options	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	☐ None <table border="1"> <tr> <td>Santen</td> <td>Non-remunerative</td> </tr> <tr> <td>Medisoft</td> <td>Non-remunerative</td> </tr> <tr> <td></td> <td></td> </tr> </table>	Santen	Non-remunerative	Medisoft	Non-remunerative			
Santen	Non-remunerative								
Medisoft	Non-remunerative								

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

FOR US-BASED AUTHORS ONLY>>> [OPEN PAYMENTS](#)

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their [Open Payments](#) record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., <https://openpaymentsdata.cms.gov/physician/1316209>). To learn more about this new requirement, please refer to [Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.](#)

Open Payments URL:

[Click or tap here to enter text.](#)

Match Disclosure Form?

YES/NO

If no, please briefly explain discrepancy:

[Click or tap here to enter text.](#)

ICMJE FORM

Date: 10/4/2023

Your Name: David F Garway-Heath

Manuscript Title: Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS)

US-based Author (if yes, you must fill out Open Payment section below): NO

Manuscript Number (if known): [Click or tap here to enter text.](#)

Ophthalmology complies with the position of the International Committee of Medical Journal Editors (ICMJE) on "Conflict of Interest." Conflict of interest for authors is defined as "financial and other conflicts of interest that might bias their work."

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)														
Time frame: Since the initial planning of the work																
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☐ None <table border="1"> <tr> <td>Moorfields Eye Hospital NHS Foundation Trust</td> <td>UKGTS trial sponsor</td> </tr> <tr> <td>Pfizer</td> <td>Unrestricted investigator-initiated research grant</td> </tr> <tr> <td>UK's NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust</td> <td>Supplementary Funding</td> </tr> <tr> <td>UCL Institute of Ophthalmology, London, UK</td> <td>Supplementary Funding</td> </tr> <tr> <td>Heidelberg Engineering</td> <td>Equipment loan</td> </tr> <tr> <td>Carl Zeiss Meditec</td> <td>Equipment loan</td> </tr> <tr> <td>Optovue</td> <td>Equipment loan</td> </tr> </table>	Moorfields Eye Hospital NHS Foundation Trust	UKGTS trial sponsor	Pfizer	Unrestricted investigator-initiated research grant	UK's NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust	Supplementary Funding	UCL Institute of Ophthalmology, London, UK	Supplementary Funding	Heidelberg Engineering	Equipment loan	Carl Zeiss Meditec	Equipment loan	Optovue	Equipment loan
Moorfields Eye Hospital NHS Foundation Trust	UKGTS trial sponsor															
Pfizer	Unrestricted investigator-initiated research grant															
UK's NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust	Supplementary Funding															
UCL Institute of Ophthalmology, London, UK	Supplementary Funding															
Heidelberg Engineering	Equipment loan															
Carl Zeiss Meditec	Equipment loan															
Optovue	Equipment loan															
Time frame: past 36 months																
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ None <table border="1"> <tr> <td>Alcon Research Institute</td> <td></td> </tr> <tr> <td>Janssen</td> <td></td> </tr> <tr> <td>Santen</td> <td></td> </tr> </table>	Alcon Research Institute		Janssen		Santen									
Alcon Research Institute																
Janssen																
Santen																

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)														
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>															
4	Consulting fees	☐ None <table border="1"> <tr><td>AbbVie</td><td></td></tr> <tr><td>Genentech</td><td></td></tr> <tr><td>Janssen</td><td></td></tr> <tr><td>Novartis</td><td></td></tr> <tr><td>Omikron</td><td></td></tr> <tr><td>Roche</td><td></td></tr> <tr><td>Santen</td><td></td></tr> </table>		AbbVie		Genentech		Janssen		Novartis		Omikron		Roche		Santen	
AbbVie																	
Genentech																	
Janssen																	
Novartis																	
Omikron																	
Roche																	
Santen																	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>															
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>															
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>															
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>															
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>															

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
11	Stock or stock options	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

FOR US-BASED AUTHORS ONLY>>> [OPEN PAYMENTS](#)

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their [Open Payments](#) record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., <https://openpaymentsdata.cms.gov/physician/1316209>). To learn more about this new requirement, please refer to [Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.](#)

Open Payments URL:

[Click or tap here to enter text.](#)

Match Disclosure Form?

YES/NO

If no, please briefly explain discrepancy:

[Click or tap here to enter text.](#)

ICMJE FORM

Date: 9/22/2023

Your Name: Giovanni Montesano

Manuscript Title: Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS)

US-based Author (if yes, you must fill out Open Payment section below): NO

Manuscript Number (if known): [Click or tap here to enter text.](#)

Ophthalmology complies with the position of the International Committee of Medical Journal Editors (ICMJE) on "Conflict of Interest." Conflict of interest for authors is defined as "financial and other conflicts of interest that might bias their work."

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" data-bbox="386 1360 1511 1465"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table> Click the tab key to add additional rows.						
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" data-bbox="386 1759 1490 1864"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	☐ None <table border="1"> <tr><td>Alcon, Inc</td><td></td></tr> <tr><td>CenterVue-iCare</td><td></td></tr> <tr><td>Omikron, SpA</td><td></td></tr> <tr><td></td><td></td></tr> </table>		Alcon, Inc		CenterVue-iCare		Omikron, SpA			
Alcon, Inc											
CenterVue-iCare											
Omikron, SpA											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None <table border="1"> <tr><td>Omikron, SpA</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Omikron, SpA							
Omikron, SpA											
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☐ None <table border="1"> <tr><td>Omikron, SpA</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Omikron, SpA							
Omikron, SpA											
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board,	☐ None <table border="1"> <tr><td>Relayer, Ltd</td><td></td></tr> </table>		Relayer, Ltd							
Relayer, Ltd											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

FOR US-BASED AUTHORS ONLY>>> [OPEN PAYMENTS](#)

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their [Open Payments](#) record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., <https://openpaymentsdata.cms.gov/physician/1316209>). To learn more about this new requirement, please refer to [Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.](#)

Open Payments URL:

[Click or tap here to enter text.](#)

Match Disclosure Form?

YES/NO

If no, please briefly explain discrepancy:

[Click or tap here to enter text.](#)

ICMJE FORM

Date: 9/23/2023

Your Name: Alessandro Rabiolo

Manuscript Title: Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS)

US-based Author (if yes, you must fill out Open Payment section below): NO

Manuscript Number (if known): [Click or tap here to enter text.](#)

Ophthalmology complies with the position of the International Committee of Medical Journal Editors (ICMJE) on "Conflict of Interest." Conflict of interest for authors is defined as "financial and other conflicts of interest that might bias their work."

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table> Click the tab key to add additional rows.						
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☐ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td>Bausch + Lomb</td> <td>Flight, hotel reservation, and congress fee for ARVO 2023 meeting</td> </tr> <tr> <td>Thea farma spa</td> <td>Flight and hotel reservation for the 2023 Moorfields International Glaucoma Symposium</td> </tr> <tr> <td>Visufarma spa</td> <td>Hotel reservation and congress fee for the the Associazione per lo Studio del Glaucoma (AISG) 2023 annual meeting</td> </tr> </table>		Bausch + Lomb	Flight, hotel reservation, and congress fee for ARVO 2023 meeting	Thea farma spa	Flight and hotel reservation for the 2023 Moorfields International Glaucoma Symposium	Visufarma spa	Hotel reservation and congress fee for the the Associazione per lo Studio del Glaucoma (AISG) 2023 annual meeting		
Bausch + Lomb	Flight, hotel reservation, and congress fee for ARVO 2023 meeting										
Thea farma spa	Flight and hotel reservation for the 2023 Moorfields International Glaucoma Symposium										
Visufarma spa	Hotel reservation and congress fee for the the Associazione per lo Studio del Glaucoma (AISG) 2023 annual meeting										
8	Patents planned, issued or pending	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
11	Stock or stock options	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

FOR US-BASED AUTHORS ONLY>>> [OPEN PAYMENTS](#)

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their [Open Payments](#) record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., <https://openpaymentsdata.cms.gov/physician/1316209>). To learn more about this new requirement, please refer to [Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.](#)

Open Payments URL:

[Click or tap here to enter text.](#)

Match Disclosure Form?

YES/NO

If no, please briefly explain discrepancy:

[Click or tap here to enter text.](#)



AMERICAN ACADEMY™
OF OPHTHALMOLOGY

Ophthalmology®, *Ophthalmology Retina™*,
Ophthalmology Glaucoma™, and *Ophthalmology Science™*
Author Contributorship Statement

The journal adheres to the Uniform Requirements set by the International Committee of Medical Journal Editors (<http://www.icmje.org/>) for authorship. To qualify for authorship, authors must make substantial contributions to the intellectual content of the paper in *each of the four* following categories:

1. Substantial contributions to conception and design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

It is the responsibility of the corresponding author, prior to submitting the manuscript, to confirm that each coauthor meets the requirements for authorship. Please list all authors of the manuscript on the Contributorship Statement form below. The form need not be uploaded at the time of original manuscript submission but rather if/when the Editorial Board invites revision.

By submitting this form, the corresponding author acknowledges that each author has read the statement on authorship responsibility and contribution to authorship. In the table below, please designate the contributions of each author. Any relevant contribution not described in the four columns can be added under "Other contributions." Please note that the list of contributions will publish with the manuscript should it be accepted. Thank you.

TITLE OF ARTICLE: **Intraocular pressure fluctuation and rates of visual field progression in primary open-angle**

glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS)

AUTHORS: Alessandro Rabiolo, Giovanni Montesano, David P Crabb, David F Garway-Heath

AUTHOR NAME	RESEARCH DESIGN	DATA ACQUISITION AND/OR RESEARCH EXECUTION	DATA ANALYSIS AND/OR INTERPRETATION	MANUSCRIPT PREPARATION
Alessandro Rabiolo	☒	☒	☒	☒
Giovanni Montesano	☐	☐	☒	☒
David P Crabb	☐	☐	☐	☒
David F Garway-Heath	☒	☒	☒	☒
	☐	☐	☐	☐
	☐	☐	☐	☐
	☐	☐	☐	☐
	☐	☐	☐	☐

OTHER CONTRIBUTIONS:

United Kingdom Glaucoma Treatment Study investigators

David F. Garway-Heath MD, David P. Crabb PhD, Catey Bunce DSc, Gerassimos Lascaratos MSc, Francesca Amalfitano BSc, Nitin Anand MD, Augusto Azuara-Blanco PhD, Rupert R. Bourne MD, David C. Broadway MD, Ian A. Cunliffe FRCOphth, Jeremy P. Diamond PhD, Scott G. Fraser MD, Tuan A. Ho MSc, Prof Keith R. Martin DM, Andrew I. McNaught MD, Anil Negi MD, Krishna Patel MSc, Richard A. Russell PhD, Ameet Shah MRCOphth, Paul G. Spry PhD, Katsuyoshi Suzuki PhD, Edward T. White BSc, Richard P. Wormald FRCOphth, Wen Xing MSc, Thierry G. Zeyen PhD